$66.05
+1.42 (+2.20%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where BMY is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
Of the 500 shown: 353 interventional · 147 observational · 114 with posted results
Held by 22 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, PRIMECAP MANAGEMENT CO/CA/, TWO SIGMA INVESTMENTS, LP, Man Group plc, Qube Research & Technologies Ltd, +17 more) · FINRA short interest 4.6 days to cover (settled 2026-07-31) · government filings 180d: 1 congress / 6 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to ZeposiaNCT07732907observationalProportion of progressive multifocal leukoencephalopathy (PML) cases by participant characteristics and potential risk factors among ozanimod-exposed participants with multiple sclerosis | — | Recruiting | Drug: Ozanimod | Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy | 15 | 2041-07-31 | in 5,460 d | 2026-07-29 |
| Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary MalignancyNCT06357754observationalParticipant in situ hybridization (ISH) or droplet-based digital Polymerase chain reaction (ddPCR) transgene testing results | — | Recruiting | Biological: Idecabtagene vicleucel, Lisocabtagene maraleucel | Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia, Multiple Myeloma | 50 | 2038-10-06 | in 4,431 d | 2026-01-22 |
| A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their OffspringNCT05953402observationalEvent rate of Major Congenital Malformations (MCM) | — | Recruiting | — | Ulcerative Colitis | 1,182 | 2034-06-30 | in 2,872 d | 2026-06-15 |
| Repotrectinib Post-Marketing Surveillance in Pediatric Patients With NTRK Fusion-Positive Tumors in JapanNCT07755826observationalNumber of participants with 1 or more adverse events (AEs) | — | Recruiting | Drug: Repotrectinib | NTRK Fusion-positive Solid Tumors | 20 | 2034-04-30 | in 2,811 d | 2026-08-10 |
| A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)NCT04196452observationalFrequency of Adverse Events (AEs) Grades 3-4 | — | Active, not recruiting | Drug: Ipilimumab | Melanoma | 10 | 2034-02-20 | in 2,742 d | 2025-11-20 |
| A Post-Authorization, Long-term Study of Ozanimod Real-world SafetyNCT05605782observationalIncidence of major adverse cardiovascular events (MACE) | — | Active, not recruiting | — | Multiple Sclerosis, Relapsing-Remitting | 9,000 | 2033-07-26 | in 2,533 d | 2025-06-26 |
| A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive MedicationsNCT04877288Proportion of participants who survive with a functional graft with estimated glomerular filtration rate (eGFR) > 30 mL/min/1.73 m2 (updated Schwartz formula) at 24 months post-randomizationRandomized · Open-label · Treatment | Phase 3 | Recruiting | Biological: Belatacept · Drug: Tacrolimus, Cyclosporine A, Mycophenolate Mofetil, Enteric Coated Mycophenolate Sodium, Corticosteroids | Renal Allograft Recipients | 102 | 2032-12-30 | in 2,325 d | 2026-06-25 |
| A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative ColitisNCT05076175Proportion of participants who achieve clinical remissionRandomized · Quadruple-masked · Treatment | Phase 2/3 | Recruiting | Drug: Ozanimod | Colitis, Ulcerative | 120 | 2032-07-12 | in 2,154 d | 2026-07-23 |
| A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their OffspringNCT05170126observationalMajor congenital malformations | — | Recruiting | — | Multiple Sclerosis | 1,182 | 2032-06-30 | in 2,142 d | 2025-11-20 |
| Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)NCT07680790Progression-Free Survival (PFS) using blinded independent central review (BICR) assessment as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)Randomized · Open-label · Treatment | Phase 3 | Not yet recruiting | Drug: Iza-bren, Osimertinib, Pemetrexed, Carboplatin, Cisplatin | Non-Small Cell Lung Cancer | 850 | 2031-12-30 | in 1,959 d | 2026-07-15 |
| A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With PsoriasisNCT06952465observationalParticipant baseline demographics | — | Active, not recruiting | Drug: Deucravacitinib · Biological: Any biologic treatment for psoriasis | Psoriasis | 2,000 | 2031-11-30 | in 1,929 d | 2025-05-01 |
| A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)NCT07361510Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Randomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: Pumitamig, Pembrolizumab | Non-Small Cell Lung Cancer (NSCLC) | 750 | 2031-10-14 | in 1,882 d | 2026-08-10 |
| A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsNCT04895709Incidence of adverse events (AEs)Randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig | Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms | 1,109 | 2031-08-31 | in 1,838 d | 2026-08-17 |
| A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionNCT07063745Progression-free survival (PFS) by RECIST v1.1Randomized · Quadruple-masked · Treatment | Phase 2/3 | Recruiting | Drug: BMS-986504, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel · Other: Placebo | Metastatic Non-small Cell Lung Cancer With MTAP Deletion | 590 | 2031-08-12 | in 1,819 d | 2026-08-10 |
| A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their InfantsNCT06126835observationalPrevalence of major congenital malformations among infants | — | Active, not recruiting | Drug: Ozanimod, Conventional therapy, Advanced therapy | Ulcerative Colitis | 2,828 | 2031-05-31 | in 1,746 d | 2024-10-01 |
| Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple SclerosisNCT06408259Annualized relapse rate (ARR)Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Ozanimod, Fingolimod · Other: Placebo | Multiple Sclerosis, Relapsing-Remitting | 194 | 2031-04-11 | in 1,696 d | 2026-04-28 |
| A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their InfantsNCT06133049observationalPrevalence of major congenital malformations among infants | — | Active, not recruiting | Drug: Ozanimod, Select DMTs other than ozanimod, No DMTs | Multiple Sclerosis | 2,961 | 2031-03-31 | in 1,685 d | 2023-11-15 |
| A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in KoreaNCT06698887observationalParticipant adverse events | — | Recruiting | Drug: Idecabtagene vicleucel | Multiple Myeloma | 15 | 2031-03-27 | in 1,681 d | 2024-12-13 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsNCT06618287Number of participants with adverse events (AEs)Randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: BMS-986507, Osimertinib, Pembrolizumab, Nivolumab, Pumitamig | Lung Cancer, Breast Cancer | 416 | 2031-02-26 | in 1,652 d | 2026-08-18 |
| Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)NCT07116967Composite cardiovascular adjudicated 3-point major adverse cardiovascular event (MACE) plus coronary revascularizationRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Deucravacitinib, Ustekinumab | Plaque Psoriasis | 3,040 | 2031-01-16 | in 1,611 d | 2026-07-23 |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)NCT07221149Objective Response (OR) (confirmed complete response (CR) or partial response (PR)) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessmentRandomized · Double-masked · Treatment | Phase 2/3 | Recruiting | Drug: Pumitamig, Folfox, Capox, Nivolumab | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | 690 | 2030-11-08 | in 1,542 d | 2026-08-12 |
| A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT06487156observationalOverall survival (OS) | — | Active, not recruiting | Drug: Nivolumab + ipilimumab | Non-small Cell Lung Cancer (NSCLC) | 404 | 2030-10-11 | in 1,514 d | 2026-01-27 |
| An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in GermanyNCT06169956observationalEvent-free survival | — | Recruiting | Drug: Neoadjuvant nivolumab in combination with platinum-based chemotherapy | Resectable Non-small Cell Lung Cancer | 400 | 2030-09-30 | in 1,503 d | 2024-04-18 |
| A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)NCT07361497Progression-free survival (PFS) by blinded independent central review (BICR) (per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Pumitamig, Durvalumab | Non-small Cell Lung Cancer (NSCLC) | 850 | 2030-09-18 | in 1,491 d | 2026-08-10 |
| First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic NeoplasmsNCT07752121observationalPercentage of participants achieving red blood cell transfusion independence (RBC-TI) for at least 8 consecutive weeks | — | Not yet recruiting | Drug: Luspatercept | Myelodysplastic Neoplasms | 190 | 2030-08-31 | in 1,473 d | 2026-08-07 |
| A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%NCT06561386Overall survival (OS) in randomized participants with PD-L1 1% to 49%Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Nivolumab, Relatlimab, Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin | Non-small Cell Lung Cancer | 1,000 | 2030-07-30 | in 1,441 d | 2026-08-17 |
| A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)NCT07195682Number of Participants With Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BMS-986506, Pumitamig, Ipilimumab | Renal Cell Carcinoma | 281 | 2030-05-03 | in 1,353 d | 2026-08-11 |
| Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)NCT01838512observationalOverall Survival (OS) for participants with relapsed/refractory multiple myeloma (RRMM) | — | Active, not recruiting | — | Multiple Myeloma | 2,555 | 2030-03-31 | in 1,320 d | 2025-12-02 |
| A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic ArthritisNCT06869551Time to first flare during the withdrawal periodRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Deucravacitinib · Other: Placebo | Juvenile Psoriatic Arthritis | 60 | 2030-03-06 | in 1,295 d | 2026-08-19 |
| A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle EastNCT07215975observationalChange in transfusion burden | — | Recruiting | Drug: Luspatercept | β-thalassemia | 200 | 2030-02-28 | in 1,289 d | 2026-08-19 |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal CancerNCT07221357Objective Response (OR) (confirmed complete response (CR) or partial response (PR)) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessmentRandomized · Double-masked · Treatment | Phase 2/3 | Recruiting | Drug: Pumitamig, FOLFOX, FOLFIRI, Bevacizumab, CAPOX | Untreated, Unresectable, or Metastatic Colorectal Cancer | 990 | 2030-02-02 | in 1,263 d | 2026-08-17 |
| A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)NCT06382987observationalChange in percent Body Surface Area (BSA) involved affected by plaque psoriasis from baseline to follow up in participants treated with deucravacitinib. | — | Recruiting | Drug: Deucravacitinib, Apremilast | Plaque Psoriasis | 600 | 2029-12-31 | in 1,230 d | 2024-04-25 |
| A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)NCT07288567Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total ScoreRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: KarXT · Other: KarXT Matching Placebo | Schizophrenia | 166 | 2029-12-18 | in 1,217 d | 2026-08-13 |
| Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in JapanNCT07383025observationalIncidence of adverse events (AEs) and/or serious AEs (SAEs) | — | Recruiting | Drug: Mavacamten | Obstructive Hypertrophic Cardiomyopathy (oHCM) | 200 | 2029-11-30 | in 1,199 d | 2026-02-03 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)NCT07293351Number of participants with adverse events (AEs)Randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Pumitamig, Ipilimumab, Cabozantinib | Advanced Renal Cell Carcinoma (RCC) | 254 | 2029-11-28 | in 1,197 d | 2026-07-30 |
| Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary FibrosisNCT07441408Number of Participants With Treatment Emergent Adverse Events (TEAEs)Open-label · Treatment | Phase 3 | Not yet recruiting | Drug: BMS-986278 | Pulmonary Fibrosis | 2,380 | 2029-11-22 | in 1,191 d | 2026-08-14 |
| A Study of BMS-986528 in Participants With Refractory Rheumatoid ArthritisNCT07412704Number of participants with treatment-emergent adverse events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1/2 | Not yet recruiting | Drug: BMS-986528 | Arthritis, Rheumatoid | 84 | 2029-10-30 | in 1,168 d | 2026-07-17 |
| A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)NCT07291076Number of participants with adverse events (AEs)Randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Pumitamig, Ipilimumab | Hepatocellular Carcinoma (HCC) | 198 | 2029-10-15 | in 1,153 d | 2026-08-18 |
| A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque PsoriasisNCT06979453Number of participants achieving at least 75% improvement in Psoriasis Area and Severity Index (PASI 75)Randomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: Deucravacitinib · Other: Placebo | Plaque Psoriasis | 366 | 2029-10-12 | in 1,150 d | 2026-08-11 |
| Pan Tumor Rollover StudyNCT03899155Incidence of Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Relatlimab, Nivolumab + Relatlimab, Capecitabine, Bevacizumab, Temozolomide, Rucaparib, Daratumumab, Regorafinib, Leucovorin, Fluorouracil, Oxaliplatin, Enzalutamide, Sunitinib, Pemetrexed, Pembrolizumab | Cancer | 1,500 | 2029-08-25 | in 1,102 d | 2026-07-29 |
| A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate CancerNCT06067841Number of participants with adverse events (AEs)Open-label · Treatment | Phase 1 | Recruiting | Drug: BMS-986460 | Metastatic Castration-resistant Prostate Cancer | 140 | 2029-08-24 | in 1,101 d | 2026-08-10 |
| A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)NCT05489705observationalIncidence rate of new or worsening heart failure due to systolic dysfunction among participants with symptomatic obstructive HCM during periods of exposure to mavacamten and other oHCM treatment | — | Recruiting | Drug: Mavacamten, Non-mavacamten symptomatic oHCM therapy | Obstructive Hypertrophic Cardiomyopathy | 1,700 | 2029-08-17 | in 1,094 d | 2026-08-19 |
| A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With AutismNCT07284745Change From Baseline in the Aberrant Behavior Checklist Irritability (ABC-I) Score at Week 8Randomized · Quadruple-masked · Treatment | Phase 3 | Not yet recruiting | Drug: KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo | Irritability Associated With Autism Spectrum Disorder | 176 | 2029-08-06 | in 1,083 d | 2026-08-03 |
| A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum DisorderNCT07285798Change From Baseline in the Aberrant Behavior Checklist Irritability (ABC-I) Score at Week 8Randomized · Quadruple-masked · Treatment | Phase 3 | Not yet recruiting | Drug: KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo | Irritability Associated With Autism Spectrum Disorder | 176 | 2029-08-04 | in 1,081 d | 2026-06-30 |
| Safety Study of Abatacept to Treat Rheumatoid Arthritis (B)NCT01088360observationalKey safety outcomes (targeted infections, malignancies, mortality) | — | Active, not recruiting | — | Rheumatoid Arthritis | 20,000 | 2029-06-30 | in 1,046 d | 2019-01-18 |
| A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)NCT06937229Number of Participants With Treatment Emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: KarXT, KarX-EC | Alzheimer Disease, Agitation | 650 | 2029-06-22 | in 1,038 d | 2026-08-19 |
| A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In IndiaNCT07459543Incidence of adverse events (AEs)Open-label · Treatment | Phase 4 | Not yet recruiting | Drug: Nivolumab + Relatlimab | Unresectable Melanoma, Metastatic Melanoma | 40 | 2029-05-26 | in 1,011 d | 2026-08-12 |
| A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)NCT07076121Progression-Free Survival as assessed by Response Evaluation Criteria in Solid Tumors version v1.1 (RECIST v1.1)Randomized · Quadruple-masked · Treatment | Phase 2/3 | Active, not recruiting | Drug: Navlimetostat, Gemcitabine, Nab-paclitaxel, Placebo | Pancreatic Ductal Adenocarcinoma | 470 | 2029-05-03 | in 988 d | 2026-06-03 |
| A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung CancerNCT07325136Number of participants with adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: BMS-986525, Pumitamig | Relapsed/Refractory Small Cell Lung Cancer | 240 | 2029-04-23 | in 978 d | 2026-08-18 |
| A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple MyelomaNCT05827016Progression-free survival (PFS)Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Iberdomide, Lenalidomide | Multiple Myeloma | 1,230 | 2029-03-15 | in 939 d | 2026-07-02 |
| Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)NCT07101094observationalParticipant medication preference as assessed by the Preference of Medication (POM) questionnaire | — | Recruiting | Drug: xanomeline and trospium chloride (X/T) therapy | Schizophrenia | 300 | 2029-01-31 | in 896 d | 2026-08-19 |
| Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After ImmunotherapyNCT07106762Phase 2: Recommended Phase 3 Dose (RP3D) of BMS-986507Randomized · Open-label · Treatment | Phase 2/3 | Recruiting | Drug: Iza-bren, Cisplatin, Gemcitabine, Carboplatin | Urothelial Cancer | 470 | 2029-01-26 | in 891 d | 2026-07-29 |
| A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid TumorsNCT06697197Number of participants with Adverse Events (AEs) as assessed by National Cancer Institute -Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0)Randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: BMS-986482, Nivolumab and rHuPH20, Nivolumab/relatlimab/rHuPH20, Bevacizumab | Advanced Solid Tumors | 413 | 2029-01-04 | in 869 d | 2026-02-03 |
| An Observational Registry of Abatacept in Patients With Juvenile Idiopathic ArthritisNCT01357668observationalIncidence rate of serious infections | — | Active, not recruiting | — | Juvenile Idiopathic Arthritis | 800 | 2029-01-02 | in 867 d | 2025-09-25 |
| A Study to Evaluate Nivolumab in Japanese Participants With Muscle-invasive Urothelial CarcinomaNCT05779592observationalDisease-free survival (DFS) | — | Active, not recruiting | — | Muscle-invasive Urothelial Carcinoma | 400 | 2029-01-02 | in 867 d | 2026-05-27 |
| A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque PsoriasisNCT04772079Observed average concentration at steady state for deucravacitinib at Week 2Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Deucravacitinib · Other: Placebo matching deucravacitinib | Plaque Psoriasis | 153 | 2029-01-01 | in 866 d | 2026-08-18 |
| A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple SclerosisNCT06396039Annualized relapse rate (ARR) over 36 monthsNon-randomized · Open-label · Treatment | Phase 4 | Active, not recruiting | Drug: BMS-986374 | Relapsing Multiple Sclerosis | 84 | 2028-12-29 | in 863 d | 2025-04-16 |
| A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)NCT06855771Number of participants who achieve Objective Response (OR) utilizing the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: BMS-986504 | Carcinoma, Non-Small-Cell Lung | 130 | 2028-12-29 | in 863 d | 2026-06-10 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.NCT06476808Number of participants with adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BMS-986463 | High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC) | 240 | 2028-12-19 | in 853 d | 2026-07-20 |
| A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in IndiaNCT05891249β-Thal Cohort: Number of participants with treatment-related adverse events (AEs) of grade 3 or higherNon-randomized · Open-label · Treatment | Phase 4 | Active, not recruiting | Biological: Luspatercept | Anemia | 85 | 2028-12-16 | in 850 d | 2025-10-20 |
| Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)NCT07100080Recommended Phase 3 Dose (RP3D) of BMS-986507Randomized · Open-label · Treatment | Phase 2/3 | Recruiting | Drug: Iza-bren, Carboplatin, Cisplatin, Pemetrexed | Non-Small Cell Lung Cancer | 500 | 2028-12-15 | in 849 d | 2026-07-29 |
| A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid TumorsNCT06997029Number of Participants With Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BMS-986500, Palbociclib, Fulvestrant | Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer | 234 | 2028-12-14 | in 848 d | 2026-07-10 |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)NCT07011732Change from baseline on the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association (CMAI-IPA) Total Score at Week 14Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo | Alzheimer Disease | 426 | 2028-11-24 | in 828 d | 2026-08-11 |
| A Study to Evaluate BMS-986511 in Adults With Major Depressive DisorderNCT07772531Mean change from baseline in Hamilton Depression Rating Scale -17 Item (HDRS-17) total scoreRandomized · Quadruple-masked · Treatment | Phase 2 | Not yet recruiting | Drug: BMS-986511, Placebo | Major Depressive Disorder | 200 | 2028-11-06 | in 810 d | 2026-08-19 |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's DiseaseNCT07011745Change from baseline on the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association (CMAI-IPA) total score at Week 14Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo | Alzheimer's Disease | 426 | 2028-11-03 | in 807 d | 2026-07-29 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid MalignanciesNCT07223047Number of participants with adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: BMS-986523, Gemcitabine, Nab-Paclitaxel, Cetuximab, Pembrolizumab | Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC) | 252 | 2028-10-13 | in 786 d | 2026-05-28 |
| Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in KoreaNCT06258668observationalNumber of participants with adverse events (AEs) | — | Recruiting | Drug: Deucravacitinib | Moderate-to-severe Plaque Psoriasis | 505 | 2028-09-30 | in 773 d | 2024-11-06 |
| A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With SchizophreniaNCT06882785Change from baseline in Positive and Negative Syndrome Scale (PANSS) total scoreRandomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: KarXT · Other: Placebo | Schizophrenia | 250 | 2028-09-23 | in 766 d | 2026-07-27 |
| A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT07680764Objective response rate (ORR) by investigator (per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1)Randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Pumitamig, Imzokitug | Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC) | 160 | 2028-09-15 | in 758 d | 2026-07-24 |
| A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)NCT06976203Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11)Randomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: KarXT, KarX-EC · Other: Placebo | Alzheimer's Disease | 586 | 2028-09-11 | in 754 d | 2026-08-12 |
| A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseaseNCT06976216Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11)Randomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: KarXT, KarX-EC · Other: Placebo | Alzheimer's Disease | 586 | 2028-09-11 | in 754 d | 2026-06-26 |
| A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)NCT04817007Incidence of adverse events (AEs)Randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: BMS-986158, Ruxolitinib, Fedratinib | Myelofibrosis | 216 | 2028-08-31 | in 743 d | 2026-05-08 |
| Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in FranceNCT06504615observationalOverall survival (OS) | — | Active, not recruiting | Drug: nivolumab + chemotherapy | Gastric Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma (EAC), Esophageal Squamous Cell Carcinoma (ESCC) | 208 | 2028-08-31 | in 743 d | 2026-04-03 |
| A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in ChinaNCT07361289observationalChange from baseline in Valsalva left ventricular outflow tract (LVOT) gradient | — | Recruiting | Drug: Mavacamten | Hypertrophic Cardiomyopathy | 500 | 2028-08-22 | in 734 d | 2026-06-18 |
| A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)NCT07492680Part 1: Number of participants who achieve Objective Response (OR)Open-label · Treatment | Phase 2 | Recruiting | Drug: BMS-986504, Daraxonrasib, Nivolumab + Relatlimab FDC, Temozolomide, Pumitamig, Pemetrexed, Carboplatin, Nab-paclitaxel, Gemcitabine, Paclitaxel | Solid Tumors | 260 | 2028-08-15 | in 727 d | 2026-07-30 |
| A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)NCT05469737Number of participants with Adverse Events (AEs) evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) criteria v.5.0Randomized · Quadruple-masked · Treatment | Phase 2/3 | Active, not recruiting | Drug: Oral Azacitidine, Placebo for Oral Azacitidine | Myelodysplastic Syndromes | 230 | 2028-07-31 | in 712 d | 2026-02-25 |
| A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid TumorsNCT07160725Number of Participants with Adverse Events (AE)Randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: BMS-986517, Pumitamig | Solid Tumours | 540 | 2028-07-31 | in 712 d | 2026-08-11 |
| Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)NCT07379827observationalTreatment titration and switch regimens as described by the prescribing clinician | — | Recruiting | Drug: Xanomeline and trospium chloride (KarXT) | Schizophrenia | 1,500 | 2028-06-20 | in 671 d | 2026-08-19 |
| A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)NCT06929273Number of participants with treatment emergent adverse events (TEAEs)Open-label · Treatment | Phase 3 | Recruiting | Drug: KarXT, Lithium, Valproate, Lamotrigine | Bipolar Disorder Type I With Mania | 450 | 2028-06-13 | in 664 d | 2026-07-24 |
| A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)NCT06701513observationalPhysician's Global Assessment (PGA) 0/1 response | — | Recruiting | Drug: Deucravacitinib | Psoriasis | 350 | 2028-04-30 | in 620 d | 2026-05-18 |
| A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).NCT06646276Overall Survival (OS)Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Biological: BMS-986489 (BMS-986012+Nivolumab), Atezolizumab · Drug: Carboplatin, Etoposide | Extensive-Stage Small Cell Lung Cancer | 530 | 2028-04-06 | in 596 d | 2026-08-14 |
| A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in KoreaNCT06073873observationalAdverse events | — | Recruiting | Drug: Ozanimod | Ulcerative Colitis | 3,000 | 2028-04-01 | in 591 d | 2024-08-22 |
| A Study to Assess Deucravacitinib Safety in PregnancyNCT07017699observationalNumber of major congenital malformations among infants | — | Recruiting | Drug: Deucravacitinib, Other systemic treatments for PsO | Psoriasis (PsO) | 900 | 2028-04-01 | in 591 d | 2025-06-12 |
| ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood TransfusionsNCT05949684Number of participants with lower-risk non-transfusion dependent myelodysplastic syndromes (NTD-MDS) who converted to Transfusion Dependence (TD) during any continuous 16-week interval within the 96-week treatment periodRandomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Biological: Luspatercept, Epoetin Alfa | Myelodysplastic Syndromes | 402 | 2028-03-24 | in 583 d | 2026-06-30 |
| A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 ImmunosuppressantsNCT07175285observationalNumber of of participants achieving Definition of Remission in Systemic Lupus Erythematosus (DORIS) at 6 months along with the 95% CI. | — | Recruiting | Drug: Current standard of care treatment options | Systemic Lupus Erythematosus (SLE) | 223 | 2028-03-24 | in 583 d | 2026-07-21 |
| A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)NCT06926868Progression-Free Survival (PFS)Randomized · Open-label · Treatment | Phase 2/3 | Recruiting | Drug: Iza-bren, Nab-paclitaxel, Paclitaxel, Capecitabine, Carboplatin, Gemcitabine | Breast Neoplasms | 600 | 2028-03-13 | in 572 d | 2026-08-10 |
| First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)NCT07679061observationalNumber of participants with grade ≥3 immune-mediated liver injury (IMLI) | — | Recruiting | Combination product: Nivolumab plus ipilimumab | Unresectable Hepatocellular Carcinoma | 200 | 2028-02-29 | in 559 d | 2026-07-01 |
| A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)NCT06947941Change From Baseline in Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions (NPI-C: H+D) ScoreRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: KarXT, KarX-EC, KarXT + KarX-EC Arm Matching Placebo | Alzheimer Disease, Psychosis | 325 | 2028-02-21 | in 551 d | 2026-06-30 |
| A Study to Evaluate the Effect of KarXT on Urological SafetyNCT07221877Change from baseline in voiding dynamics (Qmax) over timeOpen-label · Treatment | Phase 4 | Recruiting | Drug: Xanomeline/trospium chloride | Schizophrenia | 60 | 2027-12-30 | in 498 d | 2026-06-03 |
| Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene FusionNCT07599007observationalNumber of participants experiencing adverse events | — | Not yet recruiting | Drug: Repotrectinib | Non-Small Cell Lung Cancer | 10 | 2027-12-30 | in 498 d | 2026-05-20 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary FibrosisNCT06025578Number of participants that experience spontaneous syncopal eventsRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: BMS-986278, BMS-986278 Placebo | Progressive Pulmonary Fibrosis | 1,057 | 2027-12-27 | in 495 d | 2026-04-23 |
| A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung CancerNCT04794010observationalOverall survival (OS) | — | Active, not recruiting | — | Carcinoma, Non-Small-Cell Lung | 825 | 2027-12-22 | in 490 d | 2024-12-12 |
| A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemiaNCT06073860observationalNumber of participants with adverse events (AEs) | — | Recruiting | Drug: Luspatercept | Myelodysplastic Syndrome, Beta Thalassemia | 104 | 2027-12-21 | in 489 d | 2024-11-06 |
| A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With MyelofibrosisNCT06073847observationalNumber of participants with adverse events | — | Recruiting | Drug: Fedratinib | Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | 137 | 2027-12-20 | in 488 d | 2024-11-06 |
| A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)NCT07004972Incidence of serious Treatment Emergent Adverse Events (TEAEs)Open-label · Treatment | Phase 4 | Active, not recruiting | Drug: Mavacamten | Symptomatic Obstructive Hypertrophic Cardiomyopathy | 50 | 2027-12-13 | in 481 d | 2026-04-28 |
| Phase 1 Study of MRTX1719 in Solid Tumors With MTAP DeletionNCT05245500Number of Patients who Experience Dose-Limiting ToxicityNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: MRTX1719 | Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor, Pancreatic Adenocarcinoma, Advanced Solid Tumor | 336 | 2027-12-10 | in 478 d | 2025-12-05 |
| A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque PsoriasisNCT05744466observationalChange in body surface area (BSA) | — | Recruiting | Drug: Deucravacitinib, Apremilast | Psoriasis | 1,500 | 2027-12-10 | in 478 d | 2024-07-23 |
| A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin LymphomasNCT06090539Number of participants with adverse events (AEs)Randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: BMS-986458, Rituximab, Glofitamab/Obinutuzumab, Mosunetuzumab, Epcoritamab, Golcadomide | Relapsed/Refractory Non-Hodgkin Lymphoma | 460 | 2027-10-28 | in 435 d | 2026-08-18 |
| A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase DeletionNCT06672523Maximum observed concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BMS-986504, [14C]-BMS-986504 | Advanced Solid Tumors With Homozygous MTAP Deletion | 8 | 2027-10-25 | in 432 d | 2026-06-08 |
| A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant TumorsNCT06764771Number of participants with Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BMS-986488, Adagrasib, Cetuximab, Nivolumab | Advanced Malignant Tumors | 437 | 2027-10-15 | in 422 d | 2026-07-29 |
| A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid TumorsNCT06544655Incidence of adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: BMS-986484, Oxaliplatin, Capecitabine, Fluorouracil, Calcium folinate · Biological: Nivolumab | Advanced Solid Tumors | 213 | 2027-10-14 | in 421 d | 2026-04-17 |
| Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene VicleucelNCT06154902observationalOverall survival | — | Active, not recruiting | Drug: Idecabtagene vicleucel · Other: Not treated | Multiple Myeloma | 350 | 2027-07-31 | in 346 d | 2023-12-04 |
| A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid LeukemiaNCT06073769observationalNumber of participants with adverse events (AES) | — | Recruiting | Drug: Oral azacitidine | Acute Myeloid Leukemia | 154 | 2027-07-30 | in 345 d | 2024-11-06 |
| A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-ThalassemiaNCT05664737Number of participants with ≥ 50% reduction from baseline in RBC transfusion burden with a reduction of at least 2 units during any continuous 12 weeks during Week 13-48 compared to 12-week interval immediately prior to date of first doseRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Biological: Luspatercept · Drug: Placebo | Anemia | 189 | 2027-07-16 | in 331 d | 2026-08-10 |
| Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in ItalyNCT07256015observationalThe percentage of participants still receiving deucravacitinib treatment | — | Recruiting | Drug: Deucravacitinib | Psoriasis | 200 | 2027-07-05 | in 320 d | 2025-12-01 |
| A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or LamotrigineNCT07140913Change from baseline in Young Mania Rating Scale (YMRS) at Week 5Randomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: Xanomeline/Trospium Chloride, Placebo | Mania, Bipolar Disorder | 424 | 2027-06-28 | in 313 d | 2026-06-23 |
| A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid ArthritisNCT07171983Number of participants with adverse events (AEs)Randomized · Double-masked · Treatment | Phase 1 | Recruiting | Drug: BMS-986454 · Other: Placebo | Rheumatoid Arthritis | 46 | 2027-06-28 | in 313 d | 2026-07-20 |
| A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXTNCT07061288Number of participants with adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: KarXT | Schizophrenia | 116 | 2027-06-21 | in 306 d | 2026-06-12 |
| Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy ParticipantsNCT07629999Number of participants with Adverse Events (AE)Randomized · Quadruple-masked · Treatment | Phase 1 | Recruiting | Drug: BMS-986533, Famotidine, Placebo, Dabigatran Etexilate, Rosuvastatin | Healthy Volunteers | 136 | 2027-06-01 | in 286 d | 2026-07-24 |
| Antifibrotic Therapy Decision-Making in Pulmonary FibrosisNCT07722507observationalParticipant reported decision-making process for antifibrotic therapy persistence or discontinuation when considering the impact of tolerability and adverse events collected via semi-structured qualitative participant interviews | — | Not yet recruiting | Drug: Antifibrotic therapy | Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis | 40 | 2027-05-31 | in 285 d | 2026-07-23 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung CancerNCT06799286Number of participants with adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: BMS-986489 | Small Cell Lung Carcinoma | 10 | 2027-05-26 | in 280 d | 2026-05-13 |
| Mavacamten Pregnancy Surveillance ProgramNCT05939700observationalPregnancy outcomes | — | Recruiting | Drug: Mavacamten | Breastfeeding, Hypertrophic Cardiomyopathy, Pregnancy Related | 20 | 2027-04-30 | in 254 d | 2025-11-06 |
| Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative ColitisNCT07271069observationalProportion of participants achieving steroid-free symptomatic remission | — | Recruiting | Drug: Ozanimod, Azathioprine | Ulcerative Colitis (UC) | 150 | 2027-03-31 | in 224 d | 2026-05-18 |
| A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, Explore the Effect of Food After Multiple Doses of Selected Prototypes, and Evaluate Alternative Formulations of KarX and KarXT Following Single and Multiple Ascending DosesNCT07063342Maximum observed concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Trospium Chloride, Xanomeline MR, Xanomeline, Placebo | Healthy Volunteers | 236 | 2027-03-29 | in 222 d | 2026-08-17 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's DiseaseNCT06268886Change from baseline in brain tau deposition as measured by tau positron emission tomography (PET)Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: BMS-986446 · Other: Placebo | Alzheimer Disease, Early Onset | 310 | 2027-03-18 | in 211 d | 2025-07-24 |
| A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in FranceNCT04550247observationalRelapse-Free Survival (RFS) | — | Active, not recruiting | — | Melanoma | 362 | 2027-03-15 | in 208 d | 2022-03-21 |
| A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney CancerNCT03873402Progression free survival (PFS) by blinded independent central review (BICR)Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Biological: Nivolumab, Ipilimumab · Other: Ipilimumab placebo | Renal Cell Carcinoma | 437 | 2027-03-11 | in 204 d | 2026-01-21 |
| A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in ChinaNCT06512337observationalNumber of participants achieving Static Physician's Global Assessment (sPGA) 0/1 score | — | Active, not recruiting | Drug: Deucravacitinib | Plaque Psoriasis | 153 | 2027-03-11 | in 204 d | 2026-04-15 |
| A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)NCT06946797Maximum observed serum concentration (Cmax) of subcutaneous Nivolumab in serumRandomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Nivolumab, Ipilimumab, Carboplatin, Paclitaxel, Pemetrexed, Cisplatin | Non-Small Cell Lung Cancer | 76 | 2027-02-05 | in 170 d | 2026-05-14 |
| Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeNCT06419634Incidence of dose-limiting toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BMS-986497, Azacitidine, Venetoclax | Acute Myeloid Leukemia, Myelodysplastic Syndrome | 105 | 2027-02-01 | in 166 d | 2026-04-08 |
| A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their OffspringNCT06710470observationalNumber of infants born with Major Congenital Malformations (MCMs) | — | Active, not recruiting | Drug: Deucravacitinib, Systemic psoriasis medications · Other: No systemic medications | Psoriasis | 833 | 2027-01-31 | in 165 d | 2024-11-29 |
| A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)NCT06035497Number of participants with Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: BMS-986369 | Relapsed or Refractory T-cell Lymphomas | 85 | 2027-01-30 | in 164 d | 2026-05-01 |
| A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) ParticipantsNCT05811416observationalTime from ozanimod treatment initiation to ozanimod treatment permanent discontinuation | — | Active, not recruiting | — | Relapsing-remitting Multiple Sclerosis (RRMS) | 200 | 2027-01-20 | in 154 d | 2026-05-29 |
| A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid TumorsNCT07077434Maximum Plasma Concentration (Cmax) of BMS-986504Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BMS-986504 | Advanced Solid Tumors | 32 | 2027-01-19 | in 153 d | 2026-06-03 |
| A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell DiseaseNCT06481306Number of participants with adverse events (AEs)Randomized · Quadruple-masked · Treatment | Phase 1/2 | Recruiting | Drug: BMS-986470, Placebo, Famotidine, Pantoprazole | Anemia, Sickle Cell, Healthy Volunteers | 224 | 2027-01-06 | in 140 d | 2026-08-18 |
| A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in JapanNCT05161325observationalDuration of treatment | — | Active, not recruiting | — | Non-Small Cell Lung Cancer | 525 | 2026-12-31 | in 134 d | 2026-06-02 |
| A Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric CancerNCT05165264observationalOverall Survival (OS) | — | Active, not recruiting | — | Gastric Cancer | 600 | 2026-12-31 | in 134 d | 2025-03-03 |
| Real-world Patient Reported Outcomes Among Patients Treated With CamzyosNCT06551129observationalParticipant Hypertrophic Cardiomyopathy symptoms as assessed by Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ v2,0 - 7-day recall version) | — | Recruiting | Drug: Mavacamten | Obstructive Hypertrophic Cardiomyopathy | 118 | 2026-12-31 | in 134 d | 2024-11-07 |
| Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM)NCT07541833observationalChange in either resting or Valsalva Left Ventricular Outflow Tract (LVOT) peak gradient whichever used to judge the initiation of mavacamten treatment | — | Recruiting | Drug: Mavacamten | Cardiomyopathy | 36 | 2026-12-31 | in 134 d | 2026-06-26 |
| A Positron Emission Tomography Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult ParticipantsNCT07655518Percentage occupancy of M4 receptor in the brainOpen-label · Treatment | Phase 1 | Recruiting | Drug: BMS-986521 | Healthy Volunteers | 12 | 2026-12-27 | in 130 d | 2026-07-10 |
| A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult ParticipantsNCT07226817Maximum observed concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BMS-986435 | Healthy Volunteers | 240 | 2026-12-17 | in 120 d | 2026-08-12 |
| Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)NCT06122779Incidence of treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: BMS-986435 · Other: Placebo | Heart Failure | 227 | 2026-12-14 | in 117 d | 2026-07-30 |
| Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the USNCT07557498observationalParticipant blood pressure (both systolic and diastolic) | — | Recruiting | Drug: Mavacamten | Obstructive Hypertrophic Cardiomyopathy (oHCM) | 362 | 2026-12-14 | in 117 d | 2026-04-29 |
| A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal FunctionNCT07763418Maximum observed concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Not yet recruiting | Drug: Golcadomide | Kidney Failure, Chronic | 30 | 2026-12-14 | in 117 d | 2026-08-13 |
| A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132NCT06875960Number of participants treated with BMS-986165Non-randomized · Open-label · Treatment | Phase 4 | Recruiting | Drug: BMS-986165 | Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) | 35 | 2026-12-01 | in 104 d | 2026-03-30 |
| A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic CardiomyopathyNCT06146660observationalNumber of participants with adverse events | — | Recruiting | Drug: Mavacamten | Obstructive Hypertrophic Cardiomyopathy | 600 | 2026-11-30 | in 103 d | 2024-11-06 |
| A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's SyndromeNCT05946941Change from baseline in European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 52Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Deucravacitinib · Other: Placebo | Sjögren's Syndrome | 774 | 2026-11-18 | in 91 d | 2026-04-01 |
| A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.NCT07283263Number of participants with treatment-emergent adverse events (AEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Recruiting | Drug: BMS-985521 · Other: Placebo | Healthy Volunteers | 106 | 2026-11-17 | in 90 d | 2026-01-07 |
| A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)NCT06951711Change from baseline in Young Mania Rating Scale (YMRS) scoreRandomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: KarXT · Other: Placebo | Bipolar Disorder Type I With Mania or Mania With Mixed Features | 274 | 2026-11-02 | in 75 d | 2026-08-18 |
| A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I DisorderNCT06951698Change from baseline in Young Mania Rating Scale (YMRS) scoreRandomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: KarXT · Other: Placebo | Bipolar-I Disorder With Mania or Mania With Mixed Features | 274 | 2026-11-01 | in 74 d | 2026-07-27 |
| A Rollover Study of CC-122NCT05688475Number of participants with serious adverse events (SAEs) for participants who received at least 1 dose of CC-122Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: CC-122, Dexamethasone | Non-Hodgkin Lymphoma | 12 | 2026-10-31 | in 73 d | 2026-05-11 |
| Asia Myelodysplastic Syndrome (MDS) RegistryNCT07355478observationalParticipant age | — | Not yet recruiting | Drug: Prescribed treatments for myelodysplastic syndromes (MDS) | Myelodysplastic Syndromes (MDS) | 500 | 2026-10-31 | in 73 d | 2026-02-13 |
| A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)NCT05617677Proportion of participants who achieve Systemic Lupus Erythematosus Responder Index-4 [SRI(4)] responseRandomized · Double-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Deucravacitinib · Other: Placebo | Systemic Lupus Erythematosus | 516 | 2026-10-19 | in 61 d | 2025-12-03 |
| A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus ErythematosusNCT05620407Proportion of participants who achieve Systemic Lupus Erythematosus Responder Index-4 [SRI(4)] responseRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Deucravacitinib · Other: Placebo | Systemic Lupus Erythematosus | 513 | 2026-10-19 | in 61 d | 2025-12-02 |
| A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple MyelomaNCT05372354Number of participants with adverse events (AEs)Randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: CC-92480, Tazemetostat, BMS-986158, Trametinib, Dexamethasone | Multiple Myeloma | 260 | 2026-10-12 | in 54 d | 2025-09-05 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary FibrosisNCT06003426Number of participants that experience spontaneous syncopal eventsRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: BMS-986278, BMS-986278 Placebo | Idiopathic Pulmonary Fibrosis | 1,255 | 2026-10-06 | in 48 d | 2026-03-24 |
| A Real-World Study of β-Thalassemia Major Treatment With Luspatercept in TaiwanNCT06596642observationalNumber of Red Blood Cell (RBC) transfusion units received by participants | — | Active, not recruiting | Drug: Luspatercept | β-Thalassemia Major | 61 | 2026-10-01 | in 43 d | 2025-06-04 |
| Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical PracticeNCT07663786observationalOverall survival (OS) among participants treated with first-line nivolumab | — | Active, not recruiting | Drug: Nivolumab | Esophageal Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma, Gastric Adenocarcinoma | 726 | 2026-10-01 | in 43 d | 2026-06-23 |
| A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid TumorsNCT05888831Number of participants with Dose-Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: BMS-986449, Nivolumab | Advanced Solid Tumors | 100 | 2026-09-30 | in 42 d | 2025-06-11 |
| Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and CanadaNCT07718139observationalNumber of participants with pathological complete response after neoadjuvant immunotherapy and surgical resection. | — | Active, not recruiting | Biological: nivolumab, pembrolizumab, durvalumab | Non-Small Cell Lung Cancer | 300 | 2026-09-30 | in 42 d | 2026-07-21 |
| A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid TumorsNCT06730750Number of participnats with Adverse Events (AEs)Randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: BMS-986490, Bevacizumab | Advanced Solid Tumors | 360 | 2026-09-05 | in 17 d | 2026-07-02 |
| A Phase 1 Study of Navlimetostat Tablet FormulationsNCT07544628Maximum Plasma Concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Navlimetostat | Healthy Participants | 64 | 2026-08-31 | in 12 d | 2026-06-24 |
| A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic ImpairmentNCT07248839Maximum observed concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BMS-986435 | Healthy Volunteers, Hepatic Impairment | 24 | 2026-08-05 | — | 2026-06-12 |
| Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With PsoriasisNCT04036435Incidence of Adverse Events (AEs)Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: BMS-986165, Placebo | Psoriasis | 1,466 | 2026-07-25 | — | 2025-10-20 |
| A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)NCT05552976Progression-free Survival (PFS)Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Mezigdomide, Carfilzomib, Dexamethasone | Relapsed or Refractory Multiple Myeloma | 606 | 2026-07-18 | — | 2026-04-01 |
| A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic CardiomyopathyNCT06112743Composite of maximum left atrial volume index (LAVI) and left ventricular mass index (LVMI) at Week 48Non-randomized · Open-label · Treatment | Phase 4 | Active, not recruiting | Drug: Mavacamten | Cardiomyopathy, Hypertrophic | 63 | 2026-07-16actual | — | 2026-08-06 |
| A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaNCT04039607Overall Survival (OS)Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Nivolumab, Ipilimumab, Sorafenib, lenvatinib | Hepatocellular Carcinoma | 732 | 2026-07-09 | — | 2026-04-06 |
| A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or AblationNCT03383458Recurrence-free Survival (RFS)Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Biological: Nivolumab · Other: Placebo | Hepatocellular Carcinoma, Liver Cancer | 545 | 2026-05-27actual | — | 2026-07-31 |
| A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in SpainNCT07465029observationalIncidence of transfusion dependent lower-risk myelodysplastic syndromes (TD LR-MDS) | — | Active, not recruiting | Drug: Erythropoiesis-stimulating agents (ESAs), Lenalidomide, Hypomethylating agents (HMAs) · Biological: Luspatercept, Reb blood cell transfusion | Lower-risk Myelodysplastic Syndromes (TD LR-MDS) | 1,300 | 2026-03-31 | — | 2026-03-11 |
| Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT UsersNCT07571148observationalNumber of all-cause and schizophrenia-related healthcare encounters per participant | — | Active, not recruiting | Drug: KarXT (xanomeline and trospium) | Schizophrenia | 6,876 | 2026-03-25actual | — | 2026-05-06 |
| A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)NCT06140836Progression-free Survival (PFS) as per Blinded Independent Central Review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Repotrectinib, Crizotinib | Carcinoma, Non-Small-Cell Lung | 190 | 2026-03-13 | — | 2025-11-21 |
| A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder CancerNCT03661320Pathological Complete Response (pCR) rate, in all randomized participantsRandomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Biological: Nivolumab · Drug: Gemcitabine, Cisplatin | Urinary Bladder Neoplasms, Muscle-Invasive Bladder Cancer | 855 | 2026-02-16actual | — | 2026-04-15 |
| Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid LeukemiaNCT07458542observationalRelapse-free survival (RFS) | — | Active, not recruiting | Drug: Azacitidine | Acute Myeloid Leukemia (AML) | 44 | 2026-01-09actual | — | 2026-03-09 |
| A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic CardiomyopathyNCT06253221Change from baseline in Valsalva left ventricular outflow tract (LVOT) (VLVOT) gradientRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Mavacamten, Placebo | Cardiomyopathy, Hypertrophic | 44 | 2025-11-25actual | — | 2025-12-19 |
| An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete RemissionNCT05413018Relapse-free survival (RFS)Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: CC-486 · Other: Placebo | Leukemia, Myeloid, Acute | 34 | 2025-10-31actual | — | 2026-04-28 |
| A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome ParticipantsNCT06045689Number of participants who achieve red blood cell transfusion independence (RBC-TI) for 8 weeks with a simultaneous mean hemoglobin (Hb) increase of ≥ 1 g/dL from Week 1 to Week 24Non-randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Luspatercept | Myelodysplastic Syndromes | 106 | 2025-10-01actual | — | 2026-06-15 |
| COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)NCT06372457observationalParticipant age at Hypertrophic Cardiomyopathy (HCM) diagnosis | — | Active, not recruiting | Drug: Approved Hypertrophic Cardiomyopathy drug treatments, Mavacamten | Hypertrophic Cardiomyopathy (HCM) | 331 | 2025-09-29actual | — | 2026-05-04 |
| A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in GermanyNCT06104644observationalProportion of patients achieving an absolute Psoriasis Area Severity Index (aPASI) score ≤ 3 at Week 24 or nearest visit | — | Active, not recruiting | Drug: Deucravacitinib | Plaque Psoriasis | 550 | 2025-08-18actual | — | 2025-12-04 |
| A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable MelanomaNCT05625399Time-averaged serum concentration over 28 days after the first dose (Cavgd28) of NivolumabRandomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Nivolumab + Relatlimab, rHuPH20 | Melanoma | 579 | 2025-08-04actual | — | 2026-06-03 |
| A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.NCT05567458Proportion of participants with ≥ 33% reduction from baseline in red blood cell (RBC) transfusion burden over any consecutive 24 weeksRandomized · Double-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Luspatercept, Placebo | Beta-thalassemia | 94 | 2025-08-01actual | — | 2025-08-12 |
| A Study to Evaluate Treatment Patterns and Effectiveness of LuspaterceptNCT06971185observationalParticipant baseline demographics | — | Active, not recruiting | Drug: Luspatercept, Erythropoiesis-stimulating agent (ESA) | Myelodysplastic Syndromes (MDS) | 430 | 2025-08-01 | — | 2025-05-14 |
| A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has SpreadNCT04810078Time-averaged serum concentration over 28 days (Cavgd28)Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Biological: Nivolumab and rHuPH20, Nivolumab | Clear Cell Renal Cell Carcinoma | 681 | 2025-07-29actual | — | 2025-10-09 |
| Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%NCT07215962observationalIncidence of treatment-related adverse events | — | Active, not recruiting | Biological: Nivolumab + ipilimumab, Nivolumab + ipilimumab + platinum-based chemotherapy, Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy, Other dual-immuno-oncology therapy with chemotherapy | Non-small Cell Lung Cancer (NSCLC) | 300 | 2025-07-01actual | — | 2025-10-14 |
| Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of ChemotherapyNCT07024862observationalParticipant baseline socio-demographics | — | Active, not recruiting | Biological: nivolumab + ipilimumab | Metastatic Non-small Cell Lung Cancer | 100 | 2025-06-30 | — | 2025-06-17 |
| A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose CombinationsNCT06101134results2026-04-09Percentage of Evaluable Participants That Prefer SC Route of Administration Using the Patient Experience and Preference Questionnaire (PEPQ) (Question 7) After Cycle 4 Day 1 DoseNon-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Active, not recruiting | Drug: relatlimab+nivolumab, relatlimab+nivolumab+rHuPH20, nivolumab, nivolumab+rHuPH20 | Melanoma | 100 | 2025-04-10actual | — | 2026-08-19 |
| A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete RemissionNCT05197426results2026-02-11Recurrence Free Survival (RFS)Randomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Active, not recruiting | Drug: Oral Azacitidine · Other: Placebo | Acute Myeloid Leukemia | 19 | 2025-01-27actual | — | 2026-02-11 |
| A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic DrugsNCT04908202results2025-10-24Percentage of Participants With ACR 20 Response at Week 16Randomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: Deucravacitinib · Other: Placebo | Psoriatic Arthritis | 670 | 2024-09-05actual | — | 2026-04-23 |
| Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial CancerNCT03036098results2025-09-18Overall Survival (OS) in Cisplatin-ineligible Randomized Participants for Primary StudyRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Biological: Nivolumab, Ipilimumab · Drug: Gemcitabine, Cisplatin, Carboplatin | Urothelial Cancer | 1,314 | 2024-08-30actual | — | 2026-03-06 |
| A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)NCT04008030results2025-09-22Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm A All Lines Centrally Confirmed MSI-H/dMMRRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Biological: Ipilimumab, Nivolumab · Drug: Oxaliplatin, Leucovorin, Fluorouracil, Irinotecan, Bevacizumab, Cetuximab | Metastatic Colorectal Cancer | 839 | 2024-08-28actual | — | 2025-10-03 |
| A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)NCT04857034results2025-09-10Percentage Change From Baseline in CLASI Activity Score at Week 16Randomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Active, not recruiting | Drug: Deucravacitinib, Placebo | Lupus Erythematosus, Discoid, Lupus Erythematosus, Subacute Cutaneous | 74 | 2024-08-22actual | — | 2025-09-10 |
| A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the USNCT07107373observationalNew York Heart Association (NYHA) functional class | — | Active, not recruiting | Drug: Mavacamten | Obstructive Hypertrophic Cardiomyopathy (oHCM) | 150 | 2024-07-26actual | — | 2025-08-06 |
| A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor TreatmentNCT04908189results2025-04-13Number of Participants Meeting American College of Rheumatology (ACR) 20 at Week 16Randomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: Deucravacitinib, Apremilast · Other: Placebo | Psoriatic Arthritis | 729 | 2024-02-06actual | — | 2025-06-13 |
| A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)NCT04446650Maximum Tolerated Dose (MTD)Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: Fedratinib | Primary Myelofibrosis | 31 | 2023-10-05actual | — | 2025-10-21 |
| A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung CancerNCT04025879results2024-07-23Event-Free Survival (EFS) by BICRRandomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Biological: Nivolumab · Drug: Carboplatin, Cisplatin, Paclitaxel, Pemetrexed, Placebo, Docetaxel | Carcinoma, Non-Small-Cell Lung | 461 | 2023-07-26actual | — | 2025-10-16 |
| A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to MethotrexateNCT04909801results2024-10-15Percentage of SE+ Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response at Week 24Randomized · Single-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: Abatacept, Adalimumab, Methotrexate | Rheumatoid Arthritis | 338 | 2023-06-14actual | — | 2025-02-19 |
| Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C MelanomaNCT04099251results2023-07-27Recurrence Free Survival (RFS)Randomized · Triple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Biological: Nivolumab · Other: Placebo | Melanoma | 790 | 2022-06-28actual | — | 2026-08-07 |
| A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced MelanomaNCT03470922results2022-03-29Progression Free Survival (PFS)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Active, not recruiting | Biological: Relatlimab, Nivolumab | Melanoma | 714 | 2021-01-25actual | — | 2025-09-09 |
| A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell CarcinomaNCT03141177results2022-04-26Progression Free Survival (PFS)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Biological: Nivolumab, Ipilimumab · Drug: Cabozantinib, Sunitinib | Renal Cell Carcinoma | 701 | 2020-02-12actual | — | 2025-06-06 |
| A Lactation Study in Women Receiving Treatment With OzanimodNCT06181630Average concentration at steady state (Css-avg) in breast milkOpen-label · Treatment | Phase 4 | Withdrawnsponsor's stated reason: Replaced with another clinical trial | Diagnostic test: Breast milk, plasma, and blood samples | Lactating Women, Breastfed Infants | 0 | 2026-12-16 | in 119 d | 2025-12-02 |
| A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy ParticipantsNCT07422298Change from baseline Fridericia's corrected QT interval (QTcF) (ΔQTcF)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: BMS-986278, Placebo, Moxifloxacin | Healthy Volunteers | 32 | 2026-06-14actual | — | 2026-08-03 |
| Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in ChinaNCT07073690observationalParticipant red blood cell transfusion independence | — | Completed | Drug: Luspatercept | Myelodysplastic Syndromes | 88 | 2026-05-12actual | — | 2026-05-19 |
| A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of LupusNCT06013995Number of participants with adverse events (AEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: BMS-986326 · Other: Placebo for BMS-986326 | Lupus | 45 | 2026-04-14actual | — | 2026-05-26 |
| Patient Reported Outcomes and Patient Voice Among Patients Diagnosed With Low Risk Myelodysplastic Syndrome (LR-MDS) or Unexplained Anemia In JapanNCT07008820observationalParticipant quality of life as assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ C30) patient reported outcome questionnaire | — | Completed | Other: Health-related quality of life questionnaires, Qualitative interviews | Myelodysplastic Syndrome (MDS) | 56 | 2026-02-24actual | — | 2026-05-26 |
| Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating ElotuzumabNCT02719613The number of participants who received at least one dose of elotuzumab or backbone therapy (other study drugs) and the duration of treatment will be collected.Open-label · Supportive care | Phase 2 | Completed | Drug: Elotuzumab, Dexamethasone, Dexamethasone, Lenalidomide, Bortezomib, Pomalidomide, Nivolumab | Multiple Myeloma | 67 | 2026-02-23actual | — | 2026-04-15 |
| Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult ParticipantsNCT07223671Cohort 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration of AUC (0-T) of Probe Substrate With RepotrectinibNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Repotrectinib, Metformin, Digoxin, Rosuvastatin, Bupropion, Flurbiprofen, Omeprazole | Healthy Volunteers | 30 | 2026-02-19actual | — | 2026-03-27 |
| Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in FranceNCT06565975observationalParticipant real-world relapse-free survival (rw-RFS) | — | Completed | Drug: Oral azacitidine | Acute Myeloid Leukemia (AML) | 112 | 2026-01-26actual | — | 2026-02-12 |
| Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in PolandNCT07526961observationalSecond-line systemic anticancer treatment prescribed after progression/discontinuation of first-line therapy | — | Completed | Combination product: Nivolumab + Ipilimumab + Chemotherapy | Non-Small Cell Lung Cancer | 240 | 2026-01-20actual | — | 2026-04-14 |
| A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCMNCT03723655Frequency and severity of treatment-emergent adverse events and serious adverse eventsRandomized · Triple-masked · Treatment | Phase 2/3 | Completed | Drug: mavacamten | Hypertrophic Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy, Non-obstructive Hypertrophic Cardiomyopathy | 314 | 2026-01-16actual | — | 2026-02-20 |
| A Study of the Effectiveness and Safety of Nivolumab Plus Chemotherapy in Participants With Untreated Advanced/Recurrent Gastric CancerNCT05334719observationalProgression-free survival (PFS) | — | Completed | — | Stomach Neoplasms | 500 | 2026-01-16actual | — | 2026-06-18 |
| A Study to Assess the Effect of Food on the Drug Levels of AdmilparantNCT07225647Maximum observed plasma concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Admilparant | Healthy Participants | 56 | 2026-01-05actual | — | 2026-01-14 |
| Treatment Patterns and Characteristics of Patients Prescribed Opdivo QvantigNCT07636863observationalParticipant age | — | Completed | Drug: Nivolumab · Combination product: Subcutaneous nivolumab combined with hyaluronidase | Cancer | 200 | 2025-12-22actual | — | 2026-06-09 |
| Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney CancerNCT03455452observationalOverall Survival (OS) | — | Completed | — | Renal Cell Carcinoma, Renal Cell Cancer, Adenocarcinoma Of Kidney, Adenocarcinoma, Renal Cell, Kidney Cancer, Cancer of the Kidney | 623 | 2025-12-18actual | — | 2026-06-16 |
| A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male ParticipantsNCT06877702Part 1: Number of Participants With Adverse Events (AEs)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BMS-986460 | Healthy Volunteers | 85 | 2025-12-17actual | — | 2026-01-20 |
| A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been RemovedNCT03771859observationalRFS (relapse free survival) | — | Completed | — | Melanoma | 152 | 2025-12-09actual | — | 2026-06-02 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin LymphomaNCT05255601results2026-06-26Number of Participants With Dose-Limiting Toxicities (DLTs) - Part ANon-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Terminated | Drug: Relatlimab, Nivolumab | Lymphoma, Non-Hodgkin, Hodgkin Disease | 5 | 2025-12-03actual | — | 2026-06-26 |
| A Study Evaluating the Associations Between Clinical Characteristics and Use of Oral Anticoagulants in Italian Elderly Participants With Non-Valvular Atrial FibrillationNCT05232643observationalAnticoagulant (OA) cohort: Distribution of participants starting any type of anticoagulant direct-acting oral anticoagulant (DOAC) or Vitamin K antagonist (VKA) treatment | — | Completed | — | Non-Valvular Atrial Fibrillation (NVAF) | 636 | 2025-11-30actual | — | 2026-06-02 |
| A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLCNCT07141563observationalRate of pathological complete response (pCR) post-surgery | — | Completed | Drug: Nivolumab + platinum-based chemotherapy | Non-small Cell Lung Cancer (NSCLC) | 70 | 2025-11-18actual | — | 2026-01-07 |
| A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese ParticipantsNCT05136677Overall Survival (OS)Randomized · Open-label · Treatment | Phase 2 | Completed | Biological: Nivolumab, Ipilimumab · Drug: Pemetrexed, Cisplatin, Carboplatin | Mesothelioma, Malignant | 102 | 2025-11-12actual | — | 2026-01-23 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic DermatitisNCT06248814Number of participants with adverse events (AEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: BMS-986326 · Other: Placebo | Dermatitis, Atopic | 64 | 2025-11-06actual | — | 2025-12-08 |
| Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+IpilimumabNCT07091695observationalParticipant baseline demographics | — | Completed | Biological: Nivolumab + relatlimab, Nivolumab + ipilimumab | Melanoma | 100 | 2025-11-06actual | — | 2025-11-12 |
| A Study of Nivolumab in Participants With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology After Prior Chemotherapy Treated in Real World Settings in Greece and CyprusNCT05034926observationalProportion of participants surviving at the landmark timepoint of 12 months after the initiation of nivolumab treatment, in the overall study population | — | Completed | — | Non-Small Cell Lung Cancer | 212 | 2025-10-31actual | — | 2025-11-24 |
| Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer TreatmentsNCT06448793observationalResponses to qualitative interview questions | — | Completed | Drug: Approved Non-small Cell Lung Cancer (NSCLC) therapies | Non-small Cell Lung Cancer (NSCLC) | 650 | 2025-10-31actual | — | 2026-08-04 |
| A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy ParticipantsNCT06846866Part 1: Number of Participants with Non-serious Adverse Events (NSAEs)Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: BMS-986419, BMS-986419 Matching Placebo, Moxifloxacin, Moxifloxacin Matching Placebo | Healthy Volunteers | 74 | 2025-10-21actual | — | 2025-11-17 |
| A Study of Nivolumab, Ipilimumab, and Chemotherapy in Participants With Non-small Cell Lung CancerNCT05599685observationalBaseline participant and disease characteristics of interest in the overall study population and the subpopulations per NSCLC histological subtype and PD-L1 expression level | — | Completed | — | Carcinoma, Non-Small-Cell Lung | 302 | 2025-09-16actual | — | 2026-05-28 |
| A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic ImpairmentNCT06352528Maximum observed plasma concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Repotrectinib | Hepatic Impairment, Healthy Volunteers | 18 | 2025-09-16actual | — | 2025-10-06 |
| A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent HemodialysisNCT06723535Maximum observed concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BMS-986278 | Kidney Failure, Chronic, Healthy Volunteers, Renal Impairment | 27 | 2025-09-16actual | — | 2025-10-14 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy ParticipantsNCT06746402Number of participants with non-serious Adverse Events (AEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: BMS-986278, Placebo, Moxifloxacin | Healthy Volunteers | 42 | 2025-09-11actual | — | 2025-10-06 |
| A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy ParticipantsNCT06955741Geometric Mean Ratio (GMR) of Maximum Observed Serum Concentration (Cmax) of BMS-986446 Administered IV versus SCRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: BMS-986446 IV, BMS-986446 SC, Acetaminophen, Loratadine | Healthy Volunteer | 46 | 2025-09-11actual | — | 2025-10-01 |
| A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid TumorsNCT05134948Number of Participants with Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: BMS-986213 | Advanced Solid Tumors | 24 | 2025-09-01actual | — | 2025-12-03 |
| A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) RegisterNCT05413044observationalIncidence Rate of Overall Malignancies | — | Completed | — | Rheumatoid Arthritis, Psoriatic Arthritis | 140,706 | 2025-08-22actual | — | 2025-12-08 |
| A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish DatabaseNCT05421442observationalIncidence Rates of Overall Malignancies | — | Completed | — | Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) | 38,396 | 2025-08-22actual | — | 2025-12-08 |
| A Study to Evaluate Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Patients With Lower-Risk Myelodysplastic Syndromes Treated With LuspaterceptNCT07075406observationalParticipant baseline demographics | — | Completed | Drug: Luspatercept | Myelodysplastic Syndromes | 250 | 2025-08-01actual | — | 2025-08-22 |
| A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction CancerNCT06452329observationalTime to progression (TTP) | — | Completed | Drug: Nivolumab | Gastric Cancer, Gastroesophageal Junction Cancer | 260 | 2025-07-29actual | — | 2025-12-04 |
| Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric DisordersNCT06853171Number of participants with Adverse Events (AEs)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: KarXT, KarX-EC | Psychiatric Disorders | 24 | 2025-07-22actual | — | 2025-08-06 |
| A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal CancerNCT05328908Overall survival (OS) in randomized participants with programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥ 1Randomized · Open-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: Inability to meet protocol objectives | Drug: Nivolumab-relatlimab FDC, Regorafenib, TAS-102 | Colorectal Neoplasms | 770 | 2025-07-14actual | — | 2025-08-13 |
| Real-World Practice Patterns and Outcomes of Lower-Risk Myelodysplastic Syndrome Patients in JapanNCT06298643observationalParticipant age | — | Completed | Procedure: Red blood cell transfusion, Red blood cell transfusion | Lower-risk Myelodysplastic Syndromes | 177 | 2025-07-09actual | — | 2025-12-04 |
| A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver CancerNCT05337137Incidence of dose-limiting toxicities (DLTs)Randomized · Triple-masked · Treatment | Phase 1/2 | Completed | Drug: Relatlimab, Nivolumab, Bevacizumab · Other: Placebo | Carcinoma, Hepatocellular | 83 | 2025-07-05actual | — | 2026-01-12 |
| A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)NCT05658601observationalReason for switching treatment | — | Completed | — | Multiple Sclerosis, Relapsing-Remitting | 104 | 2025-07-03actual | — | 2025-10-01 |
| A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)NCT05335031observationalProportion of participants persistence with therapy | — | Completed | Drug: Ozanimod | Multiple Sclerosis, Relapsing-Remitting | 450 | 2025-06-30actual | — | 2025-09-08 |
| Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab TherapyNCT02990611observationalOverall survival (OS) of nivolumab/ipilimumab combination therapy | — | Completed | — | Melanoma | 1,087 | 2025-06-20actual | — | 2025-07-11 |
| Study to Evaluate Drug Levels of Various Solid Gastro-retentive Formulations of Deucravacitinib (BMS-986165) in Healthy ParticipantsNCT06566768Maximum observed plasma concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Deucravacitinib | Healthy Participants | 52 | 2025-06-13actual | — | 2025-07-02 |
| A Study to Evaluate Satisfaction With Care in Patients With Cancer Receiving Immunotherapy Treatment at HomeNCT06163053observationalChange in patient satisfaction on the European Organisation for Research and Treatment of Cancer satisfaction with cancer care core questionnaire (EORTC PATSAT-C33) when transitioning from Outpatient Hospital to Hospital at Home to receive immunotherapy | — | Completed | Drug: Immunotherapy | Cancer, Solid Tumors | 49 | 2025-06-12actual | — | 2026-01-14 |
| Real-Life Effectiveness and Safety in Participants With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior TherapyNCT02940639observationalOverall Survival (OS) | — | Completed | — | Renal Cell Carcinoma | 499 | 2025-06-03actual | — | 2025-07-11 |
| A Study to Evaluate the Utilization, Effectiveness, and Quality of Life of Ozanimod in Participants With Ulcerative ColitisNCT05382715observationalNumber of participants with Clinical Remission, defined by a partial Mayo Score (pMayo) of ≤1 plus an RBS=0 | — | Terminatedsponsor's stated reason: Business objectives have changed | Drug: Ozanimod | Colitis, Ulcerative | 175 | 2025-05-31actual | — | 2025-07-02 |
| A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in JapanNCT05633264observationalIncidence of Adverse Events (AEs) | — | Completed | — | Psoriasis | 369 | 2025-05-28actual | — | 2025-07-03 |
| A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung CancerNCT04702880results2026-06-17Number of Participants With Adverse EventsRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: BMS-986012, Nivolumab · Drug: Carboplatin, Etoposide | Extensive-stage Small Cell Lung Cancer | 135 | 2025-05-22actual | — | 2026-06-17 |
| A Study to Assess Health-Related Quality of Life in Patients With Hypertrophic Cardiomyopathy in JapanNCT06181617observationalParticipant age | — | Completed | Other: Quality of life assessment | Hypertrophic Cardiomyopathy | 149 | 2025-05-16actual | — | 2025-07-22 |
| A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid TumorsNCT05625412Number of participants with Adverse Events (AEs)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BMS-986360, Docetaxel, Nivolumab, Capecitabine | Advanced Solid Tumors | 70 | 2025-05-12actual | — | 2025-06-13 |
| A Study to Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic Syndromes or Beta-thalassemiaNCT07681440observationalParticipant age | — | Terminatedsponsor's stated reason: Insufficient enrollment | Drug: Luspatercept | Myelodysplastic Syndromes, Beta-thalassemia | 30 | 2025-05-01actual | — | 2026-07-02 |
| Observational Study of Nivolumab in Participants in Germany With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After Platinum-Based TherapyNCT03114163observationalOverall Survival | — | Completed | — | Head and Neck Cancer | 485 | 2025-04-28actual | — | 2025-06-18 |
| A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital PsoriasisNCT06042920results2026-04-17Percentage of Participants Achieving Palmoplantar Psoriasis Area and Severity Index (Pp-PASI)-75 ResponseRandomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 4 | Terminatedsponsor's stated reason: Business objectives have changed | Drug: Deucravacitinib, Placebo | Palmoplantar Psoriasis, Genital Psoriasis | 130 | 2025-04-25actual | — | 2026-04-17 |
| A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid MalignanciesNCT05209295AUC0-t: Estimation of area under the plasma concentration-time curve (AUC) calculated from time zero to the last measured time pointNon-randomized · Open-label · Basic science | Phase 1 | Terminatedsponsor's stated reason: Insufficient Enrollment | Drug: Onureg | Hepatic Insufficiency, Neoplasms | 2 | 2025-04-20actual | — | 2026-01-12 |
| A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence TherapyNCT04500535observationalTime to treatment failure (TTF) | — | Completed | — | Lung Cancer | 535 | 2025-04-18actual | — | 2025-11-24 |
| Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction CancerNCT06499298observationalParticipant disease-free survival (DFS) | — | Completed | Drug: Nivolumab | Esophageal Cancer, Gastroesophageal Junction Cancer | 64 | 2025-04-16actual | — | 2025-05-31 |
| Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in FranceNCT06421311observationalDisease-free survival (DFS) of participants | — | Terminatedsponsor's stated reason: Business objectives have changed | Drug: nivolumab | Urothelial Carcinoma | 176 | 2025-04-04actual | — | 2025-06-05 |
| A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy AdultsNCT06851871Maximum observed plasma concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Deucravacitinib, Famotidine | Healthy Participants | 26 | 2025-04-04actual | — | 2025-04-29 |
| Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron DatabaseNCT07079644observationalDemographics | — | Completed | Biological: Nivolumab + Relatlimab, Nivolumab + Ipilimumab, Immunotherapy monotherapy · Drug: BRAF/MEK inhibitors | Advanced Melanoma | 678 | 2025-03-31actual | — | 2025-07-23 |
| A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic SyndromesNCT06581055observationalParticipant treatment patterns: Type of treatment received | — | Withdrawnsponsor's stated reason: Sponsor decision | Drug: Luspatercept, Epoetin Alfa | Myelodysplastic Syndromes (MDS) | 0 | 2025-03-30 | — | 2024-10-09 |
| Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide RegimensNCT07689006observationalProgression-Free Survival (PFS) among participants who initiated pomalidomide-containing index regimens | — | Completed | Drug: Pomalidomide-containing regimens, Non-pomalidomide-containing regimens | Relapsed/Refractory Multiple Myeloma | 341 | 2025-03-28actual | — | 2026-07-07 |
| Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus ErythematosusNCT03920267results2026-03-20Number of Participants With Treatment-Emergent Adverse Events and Treatment Emergent Serious Adverse EventsRandomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: BMS-986165 | Systemic Lupus Erythematosus | 261 | 2025-03-21actual | — | 2026-03-20 |
| A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in TaiwanNCT06163040observationalNumber of participants with adverse events | — | Completed | Drug: Elotuzumab in combination with pomalidomide and dexamethasone, Elotuzumab in combination with lenalidomide and dexamethasone | Relapsed or Refractory Multiple Myeloma | 7 | 2025-03-17actual | — | 2025-07-31 |
| A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy ParticipantsNCT06715683Maximum Observed Plasma Concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BMS-986278 Batched method, Dose A, BMS-986278 Batched method, Dose B, BMS-986278 Continuous method | Healthy Volunteers | 48 | 2025-03-16actual | — | 2025-04-04 |
| A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United StatesNCT06851065observationalParticipant baseline demographics | — | Completed | Drug: Luspatercept, Erythropoiesis-stimulating agents | Myelodysplastic Syndromes | 418 | 2025-03-10actual | — | 2026-02-17 |
| A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC)NCT05644665Proportion of participants with clinical remission as measured by the 3-component Mayo ScoreRandomized · Triple-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Business objectives have changed | Drug: Ozanimod, Placebo | Ulcerative Colitis | 131 | 2025-03-07actual | — | 2025-03-26 |
| A Study of Mavacamten in Non-Obstructive Hypertrophic CardiomyopathyNCT05582395Change from baseline in Kansas City Cardiomyopathy Questionnaire (23-item) Clinical Summary Score (KCCQ-23 CSS) at Week 48Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Mavacamten · Other: Placebo | Cardiomyopathy, Hypertrophic | 580 | 2025-03-06actual | — | 2025-11-14 |
| A Study of BMS-986416 With and Without Nivolumab in Select Solid TumorsNCT04943900Incidence of Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BMS-986416, Nivolumab | Advanced Solid Tumors | 67 | 2025-02-27actual | — | 2025-04-09 |
| A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy ParticipantsNCT06568458Maximum Observed Serum Concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Nintedanib, BMS 986278 | Healthy Participants | 71 | 2025-02-27actual | — | 2025-03-14 |
| An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have SpreadNCT03459222results2026-04-06Number of Participants With Grade 3/Grade 4 Laboratory Test ResultsNon-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: Relatlimab, Nivolumab, Ipilimumab · Drug: BMS-986205 | Advanced Cancer | 229 | 2025-02-19actual | — | 2026-04-06 |
| Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult ParticipantsNCT06577259Maximum observed plasma concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BMS-986435 | Healthy Participants | 25 | 2025-02-19actual | — | 2025-03-14 |
| Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line TherapyNCT06422247observationalOverall survival (OS) | — | Completed | Drug: Systemic therapy | Peripheral T-cell Lymphoma | 307 | 2025-02-05actual | — | 2025-06-04 |
| An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical PracticeNCT05369832results2026-02-10Percent of Participants Achieving Clinical Response Measured by Modified Mayo Score for Cohort 1 at Week 12Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 4 | Terminatedsponsor's stated reason: Business objectives have changed. | Drug: Ozanimod | Colitis, Ulcerative | 139 | 2025-01-21actual | — | 2026-02-10 |
| Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic ImpairmentNCT06425198Maximum observed concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BMS-986278 | Hepatic Impairment, Healthy Participants | 37 | 2024-12-30actual | — | 2025-01-22 |
| A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986454 in Healthy ParticipantsNCT06086886Number of participants with adverse events (AEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: BMS-986454 · Other: Placebo | Healthy Participants | 63 | 2024-12-20actual | — | 2025-03-24 |
| A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV MelanomaNCT05002569results2026-01-08Recurrence Free Survival (RFS)Randomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Inability to meet protocol objectives | Biological: Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination | Melanoma | 1,093 | 2024-12-16actual | — | 2026-01-08 |
| A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy ParticipantsNCT06493409Maximum observed plasma concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Repotrectinib, Voriconazole, Quinidine | Healthy Volunteers | 32 | 2024-12-07actual | — | 2025-08-22 |
| An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver CancerNCT01658878results2025-12-24Number of Participants With Adverse Events (AEs)Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: Nivolumab · Drug: Sorafenib, Ipilimumab, Cabozantinib | Hepatocellular Carcinoma | 657 | 2024-11-12actual | — | 2025-12-24 |
| Real-World Effectiveness of Mavacamten in CanadaNCT06338202observationalChange in New York Heart Association (NYHA) functional class following mavacamten treatment initiation | — | Completed | Drug: Mavacamten | Obstructive Hypertrophic Cardiomyopathy (oHCM) | 115 | 2024-11-12actual | — | 2025-12-04 |
| A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid TumorsNCT03369223results2025-11-18Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) - Part 1 A and 1 BRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: BMS-986249, Nivolumab, Ipilimumab | Advanced Cancer | 356 | 2024-11-07actual | — | 2025-11-18 |
| An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has SpreadNCT03377361results2025-12-03Dose Limiting Toxicities in Part 1 and Part 1ARandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: Nivolumab, Ipilimumab · Drug: Trametinib, Regorafenib | Colorectal Cancer, Colorectal Tumors, Colorectal Carcinoma, Colorectal Neoplasm | 325 | 2024-11-04actual | — | 2025-12-03 |
| A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female ParticipantsNCT06476834results2025-12-03Maximum Observed Concentration (Cmax) of BMS-986165 and BMT-153261 in Breast MilkNon-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Deucravacitinib | Healthy Volunteers | 8 | 2024-11-02actual | — | 2025-12-03 |
| An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)NCT02477826results2025-10-30Progression-Free Survival Per BICRRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Nivolumab, Ipilimumab, Carboplatin, Cisplatin, Gemcitabine, Pemetrexed, Paclitaxel | Non-Small Cell Lung Cancer | 2,747 | 2024-10-25actual | — | 2025-10-30 |
| A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadNCT02060188results2025-11-06Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator AssessmentNon-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Ipilimumab, Nivolumab, Cobimetinib, Daratumumab, BMS-986016 | Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer, Mismatch Repair Proficient Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer | 385 | 2024-10-22actual | — | 2025-11-06 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy ParticipantsNCT06144697Incidence of adverse events (AEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Business objectives have changed | Drug: BMS-986465, Pegasys, Famotidine · Other: Placebo | Healthy Participants | 267 | 2024-10-16actual | — | 2025-02-06 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of Single Doses of BMS-986435 (MYK-224) in Healthy Chinese ParticipantsNCT06476821Maximum observed concentration (Cmax)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: BMS-986435 | Healthy Volunteers | 20 | 2024-10-11actual | — | 2024-11-19 |
| Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in FranceNCT06735781observationalRate of pathological complete response on date of surgery | — | Completed | Drug: Nivolumab | Non-small Cell Lung Cancer (NSCLC) | 101 | 2024-10-01actual | — | 2024-12-16 |
| A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional TherapyNCT05470985results2025-04-22Percentage of Participants Who Achieve Pediatric Crohn's Disease Activity Index (PCDAI) Score < 10 at Week 64Randomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2/3 | Terminatedsponsor's stated reason: Study was terminated due to business reasons. | Drug: Ozanimod | Crohn Disease | 5 | 2024-09-13actual | — | 2025-04-22 |
| A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung CancerNCT05543629results2025-03-18Number of Participants With Adverse EventsRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Business objectives have changed | Biological: BMS-986442, Nivolumab · Drug: Docetaxel, Carboplatin, Pemexetred, Paclitaxel | Advanced Solid Tumors, Non-small Cell Lung Cancer | 36 | 2024-09-12actual | — | 2025-03-18 |
| An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid CancersNCT03994601results2026-01-20Safety Related Events for Cohorts 1A, 1B and 2B.Randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: BMS-986288, Nivolumab, Regorafenib | Advanced Cancer | 219 | 2024-08-31actual | — | 2026-01-20 |
| An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have SpreadNCT03446040results2025-09-18Number of Participants With Adverse Events (AEs)Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Business objectives have changed | Biological: BMS-986258, Nivolumab · Drug: rHuPH20 | Advanced Cancer | 92 | 2024-08-29actual | — | 2025-09-18 |
| A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in JapanNCT04043975observationalObjective Response Rate (ORR) | — | Completed | — | Advanced or Metastatic Renal Cell Carcinoma | 286 | 2024-08-23actual | — | 2025-02-14 |
| A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community SettingNCT05701995results2025-09-10Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16Randomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Deucravacitinib · Other: Placebo | Psoriasis | 180 | 2024-08-23actual | — | 2026-06-03 |
| A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal CancerNCT05780736observationalDisease-free Survival (DFS) | — | Terminatedsponsor's stated reason: A decision was made to terminate the study due to expected timelines associated with start-up, participant enrollment, ethics committee approval and data availability from the study. | — | Esophageal Carcinoma, Gastroesophageal Junction Carcinoma | 33 | 2024-08-23actual | — | 2024-09-25 |
| Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid TumorsNCT04349267results2025-12-17Number of Participants With Adverse Events and DeathsNon-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: BMS-986315, nivolumab, cetuximab | Advanced Solid Tumor | 44 | 2024-08-22actual | — | 2025-12-17 |
| A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid TumorsNCT05407675results2025-10-03Number of Participants With Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: BMS-986408, Rabeprazole · Biological: Nivolumab, Ipilimumab, Platinum-doublet chemotherapy | Advanced Solid Tumors | 68 | 2024-08-22actual | — | 2026-08-13 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic CardiomyopathyNCT05556343results2026-06-02Part A: Number of Participants With Adverse Events and Serious Adverse EventsNon-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Business objectives have changed | Drug: MYK-224 | Cardiomyopathy, Hypertrophic | 18 | 2024-08-19actual | — | 2026-06-02 |
| A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced TumorsNCT05298592Number of participants with adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Biological: BMS-986406, Nivolumab · Drug: Carboplatin, Pemetrexed, Paclitaxel | Advanced Cancer | 77 | 2024-08-16actual | — | 2024-09-26 |
| A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)NCT05577715results2025-09-04Objective Response Rate as Per InvestigatorRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Business objectives have changed | Drug: MORAb-202 | Carcinoma, Non-Small-Cell Lung | 31 | 2024-08-12actual | — | 2025-09-04 |
| A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)NCT06094296results2025-04-16Number of Participants With Adverse Events (AEs) for Part 1Randomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Business objectives have changed | Drug: BMS-986315, Nivolumab, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel | NSCLC | 1 | 2024-08-08actual | — | 2025-04-16 |
| A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe PsoriasisNCT05730725results2025-11-25Percentage of Participants Achiving PASI-75 at Week 12Randomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: BMS-986322 · Other: Placebo | Psoriasis | 109 | 2024-08-06actual | — | 2025-11-25 |
| Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory DrugsNCT06160167observationalIncidence of hyperpigmentation in Black participants exposed to IMiDs to non-IMiDs for MM | — | Completed | Drug: IMiD treatment, No IMiD treatment, Systemic therapy | Multiple Myeloma | 4,204 | 2024-08-01actual | — | 2024-08-23 |
| A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic SyndromesNCT05168202results2025-09-25Number of Participants With DLTsNon-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Business objectives have changed | Drug: CC-95251, Azacitidine, Venetoclax | Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | 56 | 2024-07-30actual | — | 2025-09-25 |
| A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the BladderNCT05742867observationalOverall survival | — | Completed | — | Urinary Bladder Neoplasms | 115 | 2024-07-10actual | — | 2025-01-23 |
| Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid TumorsNCT02966548Number of adverse events (AE)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Relatlimab, Nivolumab | Cancer | 35 | 2024-07-09actual | — | 2025-02-17 |
| A Study of Nivolumab in Patients With Head and Neck Cancer.NCT04050761observationalOverall Survival | — | Completed | Biological: Nivolumab | Squamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and Neck | 502 | 2024-07-08actual | — | 2025-07-02 |
| A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder CancerNCT05496192Proportion of Participants That Prefer Nivolumab SC at the First Assessment of Patient Preference Using Patient Experience and Preference Questionnaire (PEPQ) (Question 1)Non-randomized · Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Replaced it with another clinical trial | Drug: Nivolumab/rHuPH20, Nivolumab | Melanoma, Urothelial Carcinoma | 0 | 2024-06-24 | — | 2023-04-14 |
| A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube CancerNCT05613088results2025-07-03Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator AssessmentRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: MORAb-202, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan | Neoplasms, Ovarian | 106 | 2024-06-17actual | — | 2026-04-30 |
| A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy ParticipantsNCT06211179Maximum observed concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Treatment A: Mavacamten intact oral capsule, Treatment B: Mavacamten open capsule in suspension, Treatment C: Mavacamten open capsule in suspension administered via nasogastric tube (NGT) | Healthy Volunteers | 34 | 2024-06-13actual | — | 2024-09-19 |
| An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in AustraliaNCT04146324observationalPercentage of Participants with Relapse-Free Survival (RFS) | — | Completed | Drug: nivolumab | Melanoma | 150 | 2024-05-31actual | — | 2025-01-24 |
| A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line TreatmentNCT02927769results2025-02-10Complete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Blinded Independent Centralized Review (BICR) - Cohort 1Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Nivolumab, brentuximab vedotin, bendamustine | Hodgkin Disease | 72 | 2024-05-28actual | — | 2025-02-10 |
| An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid TumorsNCT01968109results2026-01-06Number of Participants With Adverse Events, Deaths and Clinically Relevant Laboratory AbnormalitiesRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: Relatlimab, Nivolumab, BMS-986213 | Neoplasms by Site | 1,482 | 2024-05-22actual | — | 2026-04-06 |
| DeteCtiON and Stroke PreventIon by MoDEl ScRreenING for Atrial FibrillationNCT05838781Incident AFRandomized · Open-label · Diagnostic | Not applicable | Completed | Diagnostic test: Risk prediction model, 14-days continuous ECG monitoring | Atrial Fibrillation, Atrial Flutter | 2,112 | 2024-05-16actual | — | 2024-05-22 |
| A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid TumorsNCT06024174results2025-07-22Part 1: Number of Participants With Dose Limiting Toxicity (DLTs)Randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Business objectives have changed | Drug: BMS-986466, Adagrasib, Cetuximab | Advanced Solid Tumors | 5 | 2024-05-13actual | — | 2025-07-22 |
| A Retrospective Cohort Study of Mavacamten Patient Support Program in CanadaNCT06549608observationalParticipant demographics | — | Completed | Drug: Mavacamten | Hypertrophic Cardiomyopathy | 683 | 2024-05-06actual | — | 2026-06-12 |
| Apixaban for the Acute Treatment of Venous Thromboembolism in ChildrenNCT02464969results2024-10-29Percentage of Participants With Composite of Major and Clinically Relevant Non-Major (CRNM) BleedingRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Apixaban, Standard of Care | Venous Thromboembolism | 229 | 2024-04-30actual | — | 2024-10-29 |
| A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid TumorsNCT05678283Total [14C]-radioactivity in whole blood, plasma, urine, and feces (and vomit, if applicable)Non-randomized · Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: Business Objectives have changed. | Drug: [14C]CC-90010, CC-90010 | Advanced Solid Tumors | 0 | 2024-04-29 | — | 2024-04-17 |
| A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced CancersNCT03400332results2025-06-19Number of Participants Experiencing Adverse Events (AEs) - Part 1Randomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: BMS-986253 · Biological: Nivolumab, Ipilimumab · Other: Placebo | Cancer, Melanoma | 281 | 2024-04-26actual | — | 2026-02-24 |
| An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid CancersNCT03956680Incidence of dose-limiting toxicity (DLTs)Open-label · Treatment | Phase 1 | Completed | Drug: BMS-986301 · Biological: Nivolumab, Ipilimumab | Advanced Solid Cancers | 54 | 2024-04-17actual | — | 2025-02-19 |
| A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of MidazolamNCT05901714Maximum observed plasma concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Afimetoran, Phenytoin, Midazolam | Healthy Participants | 65 | 2024-04-11actual | — | 2024-08-07 |
| First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid TumorsNCT03110107results2025-04-24Number of Participants With Adverse Events (AEs)Randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Business Objectives have changed. | Biological: Ipilimumab, BMS-986218, Nivolumab | Advanced Cancer | 376 | 2024-04-04actual | — | 2025-04-24 |
| Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) PatientsNCT06345183observationalParticipant year of birth | — | Completed | Combination product: Nivolumab + Ipilimumab combination therapy, Pembrolizumab + Lenvatinib combination therapy | Advanced Renal Cell Carcinoma (aRCC) | 327 | 2024-04-04actual | — | 2025-11-06 |
| Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology PracticeNCT02847728observationalIncidence rate of and severity of immune-related pneumonitis - Melanoma | — | Completed | — | Melanoma, Lung Cancer | 1,189 | 2024-03-31actual | — | 2024-06-03 |
| A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by SurgeryNCT04026412results2025-07-24Arm A Vs Arm C - Progression-Free Survival (PFS) by RECIST 1.1 Per Blinded Independent Central Review (BICR)Randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: nivolumab, ipilimumab, durvalumab | Non-Small Cell Lung Cancer (NSCLC) | 925 | 2024-03-22actual | — | 2025-07-24 |
| A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart FailureNCT05952089Maximum observed plasma concentration (Cmax)Open-label · Treatment | Phase 1 | Completed | Drug: Danicamtiv, Midazolam | Heart Failure With Reduced Ejection Fraction | 13 | 2024-03-15actual | — | 2024-04-04 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy ParticipantsNCT04736134Number of participants with adverse events (AEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Biological: BMS-986326, Multiple Ascending Dose SC · Other: Placebo matching BMS-986326, Multiple Ascending Dose Placebo | Healthy Participants | 88 | 2024-03-14actual | — | 2024-05-06 |
| A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986446 in Healthy Participants and Healthy Participants of Japanese EthnicityNCT06084598Incidence of adverse events (AEs)Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: BMS-986446 · Other: Placebo | Healthy Participants | 24 | 2024-03-08actual | — | 2024-03-15 |
| Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma ParticipantsNCT04495010Event-free survival (EFS)Randomized · Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Business objectives have changed | Biological: Nivolumab, Ipilimumab | Melanoma | 0 | 2024-02-28 | — | 2021-03-19 |
| A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnTNCT04766892results2025-03-20Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: mavacamten | Heart Failure With Preserved Ejection Fraction | 30 | 2024-02-26actual | — | 2025-03-20 |
| Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other CausalitiesNCT04572893results2025-05-21Number of Participants With Adverse Events (AEs) in Part AOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Business objectives have changed | Drug: danicamtiv | Primary Familial Dilated Cardiomyopathy | 41 | 2024-02-22actual | — | 2025-05-21 |
| A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete ResectionNCT05297565results2025-02-27Number of Participants With Adverse EventsRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Nivolumab/rHuPH20, Nivolumab | Melanoma | 14 | 2024-02-08actual | — | 2025-02-27 |
| A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid TumorsNCT02913313results2025-04-20Number of Participants With Adverse EventsNon-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: BMS-986207 · Biological: Nivolumab, Ipilimumab | Broad Solid Tumor | 101 | 2024-01-25actual | — | 2025-04-20 |
| Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in CanadaNCT06361563observationalParticipant sociodemographics | — | Completed | Drug: Nivolumab | Upper Gastrointestinal Cancer | 250 | 2024-01-25actual | — | 2024-04-12 |
| Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in CanadaNCT06361576observationalParticpant sociodemographics | — | Completed | Drug: Nivolumab | Upper Gastrointestinal Cancer | 700 | 2024-01-25actual | — | 2024-04-12 |
| A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has SpreadNCT04540705Incidence of adverse events (AEs) by severity (Part 1)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Biological: Nivolumab · Drug: Axitinib, Cabozantinib | Renal Cell Carcinoma | 30 | 2024-01-18actual | — | 2024-02-28 |
| Study of Relatlimab in Combination With Nivolumab in Chinese ParticipantsNCT05498480Number of Participants with Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Biological: Relatlimab, Nivolumab | Advanced Solid Tumors | 6 | 2024-01-18actual | — | 2024-02-20 |
| A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)NCT04623775results2025-03-18TRAEs Leading to Discontinuation Within 12 Weeks of First Dose in Part 1Randomized · Triple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Nivolumab, Relatlimab · Drug: Carboplatin, Cisplatin, Paclitaxel, Nab-Paclitaxel, Pemetrexed | Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer | 468 | 2024-01-11actual | — | 2026-06-18 |
| Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp PsoriasisNCT05478499results2025-03-13Percentage of Participants With a Scalp-specific Physician Global Assessment Score of 0 or 1 (Ss-PGA 0/1) at Week 16Randomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Deucravacitinib · Other: Placebo | Psoriasis | 154 | 2024-01-11actual | — | 2025-10-28 |
| A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia AreataNCT05556265results2025-02-28Change From Baseline in Severity of Alopecia Tool Score at Week 24 in Placebo-Controlled Treatment PeriodRandomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Business objectives have changed | Drug: Deucravacitinib · Other: Placebo | Alopecia Areata | 94 | 2024-01-06actual | — | 2025-05-31 |
| A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid TumorsNCT03195478results2025-09-15Number of Participants With Adverse Events (AEs) in Part 1.Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Nivolumab, Ipilimumab | Solid Tumor | 37 | 2024-01-05actual | — | 2025-09-15 |
| A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in IndiaNCT04513522results2025-07-11Total Number of Participants Experiencing High Grade Immune-Mediated Adverse Events (IMAE)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 4 | Completed | Biological: Nivolumab, Ipilimumab | Kidney Neoplasms | 101 | 2024-01-04actual | — | 2025-07-11 |
| Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior ChemotherapyNCT02910999observationalOverall Survival (OS) | — | Completed | — | Non-Small Cell Lung Cancer | 868 | 2023-12-31actual | — | 2024-05-13 |
| A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male ParticipantsNCT06088264Maximum observed in plasma/whole blood concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BMS-986322 | Healthy Male Participants | 8 | 2023-12-22actual | — | 2024-03-29 |
| A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple SclerosisNCT05064436results2025-04-24Number of Participants With Adverse Events Based on Severity.Non-randomized · Open-label · DiagnosticStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Business objectives have changed | Drug: 11C-BMS-986196 | Multiple Sclerosis (MS) | 10 | 2023-12-18actual | — | 2025-04-24 |
| A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and ChemotherapyNCT04151563Overall Reponse Rate (ORR) using RECIST 1.1 per Blinded Independent Central Review (BICR) assessmentRandomized · Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Business objectives have changed | Biological: nivolumab, ipilimumab, docetaxel, ramucirumab · Drug: cabozantinib, lucitanib | Carcinoma, Non-small Cell Lung Cancer | 0 | 2023-12-17 | — | 2023-12-19 |
| A Study to Evaluate the Drug Levels of Abatacept Converted From Drug Substance by Two Different Processes in Healthy ParticipantsNCT05981976Maximum observed serum concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Biological: Abatacept | Healthy Participants | 174 | 2023-12-14actual | — | 2024-07-29 |
| A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy ParticipantsNCT05615012Maximum observed plasma concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BMS-986322, Rosuvastatin, Metformin, Methotrexate, Leucovorin · Dietary supplement: Glucose | Healthy Participants | 76 | 2023-12-13actual | — | 2024-03-27 |
| A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver CancerNCT04340193results2024-11-26Number of Participants With Adverse EventsRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: nivolumab, ipilimumab · Procedure: TACE | Cancer, Hepatocellular | 26 | 2023-12-12actual | — | 2024-11-26 |
| A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female ParticipantsNCT05985590Maximum observed plasma concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BMS-986278, Drospirenone/Ethinyl Estradiol | Healthy Volunteers | 37 | 2023-12-11actual | — | 2024-01-24 |
| A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate CancerNCT05169684results2025-06-10Number of Participants With Treatment Related Adverse EventsRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Business objectives have changed | Biological: BMS-986218, Nivolumab · Drug: Docetaxel | Prostatic Neoplasms, Castration-Resistant | 10 | 2023-12-06actual | — | 2025-06-10 |
| A Study to Evaluate the Effect of Food on the Drug Levels of BMS-986196 in Healthy Adult ParticipantsNCT06034899Area under the serum concentration-time curve from time zero to time of last quantifiable concentration (AUC [0-T])Randomized · Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: Business objectives have changed. | Drug: BMS-986196 | Healthy Adult Volunteers | 0 | 2023-11-30 | — | 2023-09-21 |
| A Study of Mavacamten in Obstructive Hypertrophic CardiomyopathyNCT05414175results2024-12-04Change From Baseline in Post-exercise Left Ventricular Outflow Tract (LVOT) Peak Gradient at Week 30Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Mavacamten | Cardiomyopathy, Hypertrophic Obstructive | 38 | 2023-11-27actual | — | 2026-01-27 |
| A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy ParticipantsNCT05760937Number of Participants with Adverse Events (AEs)Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: BMS-986447, Placebo | Healthy Participants | 32 | 2023-11-27actual | — | 2024-04-05 |
| Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice SettingsNCT02758769observationalPercentage of achievement in simplified disease activity index (SDAI) remission after administration of abatacept | — | Completed | Biological: ORENCIA Subcutaneous Injection | Rheumatoid Arthritis | 303 | 2023-11-15actual | — | 2025-06-22 |
| A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult ParticipantsNCT06027437Maximum observed plasma concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Danicamtiv | Healthy Volunteers | 21 | 2023-11-10actual | — | 2023-11-29 |
| Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEERNCT03496168results2025-01-09Number of Participants With Treatment Emergent Adverse Events and Treatment Emergent Serious Adverse EventsOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: mavacamten | Hypertrophic Cardiomyopathy | 13 | 2023-11-09actual | — | 2025-01-09 |
| A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)NCT04149574results2025-09-16Part 2: Event Free SurvivalRandomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Insufficient enrollment, inability to meet protocol objectives, and slow accrual. | Drug: nivolumab · Other: Placebo · Biological: Bacillus Calmette-Guérin (BCG) | Urinary Bladder Neoplasms | 13 | 2023-10-31actual | — | 2025-09-16 |
| A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy ParticipantsNCT05932303Maximum observed plasma concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BMS-986278, Itraconazole, Gemfibrozil, Carbamazepine | Healthy Participants | 47 | 2023-10-23actual | — | 2023-10-30 |
| A Study to Evaluate the Drug Levels, Physical and Chemical Changes, and Removal of BMS-986196 in Healthy Male ParticipantsNCT05981963Total Radioactivity (TRA): Maximum observed plasma concentration (Cmax)Open-label · Treatment | Phase 1 | Completed | Drug: [14C]-BMS-986196 | Healthy Male Volunteers | 8 | 2023-10-22actual | — | 2023-11-13 |
| A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult ParticipantsNCT05963932Maximum observed plasma concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BMS-986419 DR Capsule, BMS-986419 IR Tablet | Healthy Volunteers | 60 | 2023-10-17actual | — | 2024-01-23 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese ParticipantsNCT05813717Number of participants with Adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: BMS-986325, Placebo | Healthy Volunteers | 25 | 2023-10-02actual | — | 2023-11-07 |
| A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy ParticipantsNCT05866627Maximum observed plasma concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Famotidine, Afimetoran | Healthy Volunteers | 32 | 2023-09-29actual | — | 2026-05-13 |
| A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a KidneyNCT03138512results2024-12-18Disease-Free Survival (DFS) by BICR - Treatment Part A and BRandomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: nivolumab, ipilimumab · Drug: nivolumab placebo, ipilimumab placebo | Carcinoma, Renal Cell | 1,641 | 2023-09-28actual | — | 2024-12-18 |
| A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With MelanomaNCT06163170observationalIncidence of treatment-related adverse events | — | Completed | Drug: Nivolumab +/- ipilimumab, Nivolumab | Melanoma | 100 | 2023-09-25actual | — | 2024-04-18 |
| A Study of Mezigdomide in Healthy Participants and Participants With Hepatic ImpairmentNCT05707390Maximum observed concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Mezigdomide | Hepatic Impairment | 32 | 2023-09-13actual | — | 2024-02-07 |
| A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy ParticipantsNCT05932277Maximum observed plasma concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BMS-986419, Caffeine, Bupropion, Flurbiprofen, Omeprazole, Midazolam, Fexofenadine | Healthy Volunteers | 22 | 2023-09-13actual | — | 2023-10-30 |
| A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase InhibitorsNCT04567615results2024-10-08Objective Response Rate(ORR) Assessed by BICRRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Nivolumab, Relatlimab | Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult, Liver Cell Carcinoma, Liver Cell Carcinoma, Adult | 266 | 2023-08-31actual | — | 2026-01-08 |
| A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative ColitisNCT04877990results2024-09-24Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Deucravacitinib | Crohn Disease, Ulcerative Colitis | 67 | 2023-08-29actual | — | 2024-09-24 |
| A Study to Evaluate the Drug-drug Interaction of BMS-986196 With Oral Contraceptives in Healthy Female ParticipantsNCT05891262Maximum observed plasma concentration (Cmax)Open-label · Treatment | Phase 1 | Completed | Drug: BMS-986196, Loestrin | Healthy Female Volunteers | 15 | 2023-08-25actual | — | 2023-09-25 |
| A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy ParticipantsNCT05852769Maximum observed plasma concentration (Cmax)Open-label · Treatment | Phase 1 | Completed | Drug: BMS-986196, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, Pravastatin | Healthy Volunteers | 18 | 2023-08-24actual | — | 2023-09-26 |
| Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)NCT04267393results2024-09-04Percentage of Participants Who Achieve ≥ 1 Stage Improvement in Liver Fibrosis (NASH CRN Fibrosis Score), as Determined by Liver Biopsy After 12 Weeks of Treatment.Randomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Trial terminated because of lack of efficacy in the short term acute phase. | Drug: BMS-986263 · Other: Placebo | Nonalcoholic Steatohepatitis (NASH) | 124 | 2023-08-16actual | — | 2024-09-04 |
| A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian ParticipantsNCT05806359Number of Participants with Adverse Events (AEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Danicamtiv, Placebo | Healthy Volunteers | 33 | 2023-08-14actual | — | 2024-05-23 |
| A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) TreatmentNCT03978611Number of Participants with Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Business objectives have changed. | Drug: Relatlimab, Ipilimumab | Melanoma | 11 | 2023-07-26actual | — | 2024-07-24 |
| BMS-986325 in Healthy Participants and Participants With Primary Sjögren's SyndromeNCT04684654Incidence of Adverse Events (AEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Insufficient enrollment | Biological: BMS-986325 · Other: Placebo for BMS-986325 | Healthy Participants, Primary Sjögren's Syndrome | 118 | 2023-07-25actual | — | 2023-08-23 |
| A Study to Evaluate the Effects of Mavacamten in Healthy ParticipantsNCT05719805Maximum observed plasma concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Mavacamten | Healthy Participants | 84 | 2023-07-25actual | — | 2023-10-12 |
| A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-RuxolitinibNCT05665192observationalPercentage change in Total Symptom Score (TSS) assessed by Myelofibrosis Symptom Assessment Form (MFSAF) | — | Completed | — | Myelofibrosis | 150 | 2023-07-24actual | — | 2025-04-08 |
| A Phase 1, First-in-Human Study of BMS-986421 in Healthy ParticipantsNCT05517837Number of participants with adverse events (AEs)Randomized · Double-masked · Treatment | Early Phase 1 | Terminatedsponsor's stated reason: Adverse change in the risk/benefit. | Drug: BMS-986421 · Other: Placebo | Healthy Participants | 46 | 2023-07-14actual | — | 2023-09-13 |
| A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult ParticipantsNCT05899738Maximum Observed Plasma Concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Iberdomide | Healthy Volunteers | 32 | 2023-07-06actual | — | 2024-07-26 |
| A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy ParticipantsNCT05658146Maximum Observed Serum Concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Mavacamten Capsule 1, Mavacamten Capsule 2, Mavacamten Capsule 3 | Healthy Participants | 95 | 2023-07-05actual | — | 2023-10-11 |
| A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male ParticipantsNCT05847439Maximum observed plasma concentration (Cmax)Open-label · Treatment | Phase 1 | Completed | Drug: [14C]BMS-986419 | Healthy Volunteers | 8 | 2023-07-05actual | — | 2023-10-02 |
| A Study to Determine if Identification of Undiagnosed Atrial Fibrillation in People at Least 70 Years of Age Reduces the Risk of StrokeNCT04126486Incidence of all strokes leading to hospitalizationRandomized · Open-label · Prevention | Phase 4 | Completed | Other: Zio®XT Monitor | Atrial Fibrillation, Atrial Flutter | 11,931 | 2023-06-30actual | — | 2023-07-12 |
| A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)NCT05324436observationalIncidence of Adverse Events (AEs) | — | Completed | — | Mesothelioma, Malignant | 75 | 2023-06-30actual | — | 2025-01-20 |
| A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy ParticipantsNCT05638282Maximum Observed Serum Concentration (Cmax)Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: Cendakimab, Placebo | Healthy Participants | 25 | 2023-06-27actual | — | 2023-08-01 |
| A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder CancerNCT04209114results2024-06-27Pathologic Complete Response (pCR) Rate- Nivolumab + Bempegaldesleukin Compared to Standard of CareRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Nivolumab, Bempegaldesleukin · Procedure: Radical cystectomy (RC) | Bladder Cancer, Bladder Tumor, Muscle-Invasive Bladder Cancer | 114 | 2023-06-07actual | — | 2024-06-27 |
| A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic CancerNCT03336216results2024-07-23Progression Free Survival (PFS) by BICRRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Cabiralizumab, Nivolumab · Drug: Nab-paclitaxel, Onivyde, Fluorouracil, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan Hydrochloride | Advanced Pancreatic Cancer | 205 | 2023-06-01actual | — | 2024-07-23 |
| A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate CancerNCT04100018results2024-07-22Radiographic Progressive Free Survival (rPFS) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group 3 (PCWG3)Randomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Nivolumab · Drug: Prednisone, Docetaxel · Other: Placebo | Prostate Cancer | 1,030 | 2023-06-01actual | — | 2025-06-12 |
| A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female ParticipantsNCT05579574Maximum observed plasma concentration (Cmax) for EE/NETNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BMS-986322, Loestrin | Healthy Participants | 42 | 2023-06-01actual | — | 2023-08-18 |
| A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative ColitisNCT04613518results2024-07-12Percentage of Participants in Clinical Response at Week 12Randomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: BMS-986165 · Other: Placebo Comparator | Colitis, Ulcerative | 38 | 2023-05-31actual | — | 2024-07-12 |
| A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese ParticipantsNCT05805904Maximum observed concentration (Cmax)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: BMS-986278, Placebo | Healthy Volunteers | 24 | 2023-05-23actual | — | 2023-09-18 |
| A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT05244070Number of participants with adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Business objectives have changed. | Drug: BMS-986403, Fludarabine, Cyclophosphamide | Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma | 5 | 2023-05-04actual | — | 2023-07-18 |
| A Study to Evaluate the Drug Exposure of Single Ascending Doses of BMS-986369 and the Effect of Food on the BMS-986369 in Healthy ParticipantsNCT05350800Maximum observed plasma concentration (Cmax)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: BMS-986369 | Healthy Volunteer | 68 | 2023-05-04actual | — | 2024-07-05 |
| A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)NCT05684289Mean placebo-corrected change from baseline in systolic blood pressure (SBP) (Part 1)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: BMS-986278, Sildenafil, Placebo | Healthy Participants | 61 | 2023-05-02actual | — | 2023-08-24 |
| A Study to Assess Treatment Patterns, Clinical Outcomes and Healthcare Resource Utilization Among Adult Participants With Moderate-To-Severe Plaque PsoriasisNCT05547490observationalDistribution of demographic characteristics: Age | — | Completed | — | Psoriasis | 3,506 | 2023-04-28actual | — | 2023-12-18 |
| A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic TherapyNCT05432622observationalTime to Treatment Discontinuation (TTD) | — | Completed | — | Melanoma | 95 | 2023-04-26actual | — | 2024-01-18 |
| A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus ErythematosusNCT04493541Incidence of Serious Adverse Events (SAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: BMS-986256 · Other: BMS-986256 Placebo | Lupus Erythematosus, Cutaneous | 13 | 2023-04-21actual | — | 2023-05-09 |
| A Study to Evaluate the Absorption, Metabolism, and Excretion (ADME) of BMS-986435NCT05686096Maximum observed concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: MYK-224 | Healthy Volunteers | 7 | 2023-04-08actual | — | 2023-05-25 |
| A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese DescentNCT05546151Number of participants with serious adverse events (SAEs)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: BMS-986322 · Other: Placebo for BMS-986322 | Healthy Participants | 24 | 2023-04-07actual | — | 2023-06-22 |
| A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid TumorsNCT03184870results2025-10-09Number of Participants Experiencing Adverse Events (AEs)Randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: BMS-813160, Nab-paclitaxel, Gemcitabine, 5-fluorouracil (5-FU), Leucovorin, Irinotecan · Biological: Nivolumab | Colorectal Cancer, Pancreatic Cancer | 332 | 2023-04-06actual | — | 2025-10-09 |
| Mavacamten in Obstructive Hypertrophic CardiomyopathyNCT07168655observationalParticipant New York Heart Association (NYHA) functional class | — | Completed | Drug: Mavacamten | Obstructive Hypertrophic Cardiomyopathy (oHCM) | 163 | 2023-03-31actual | — | 2025-09-11 |
| A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)NCT05218902observationalIncidence of Adverse Events (AEs) | — | Completed | — | Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute | 290 | 2023-03-20actual | — | 2023-05-31 |
| An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual DiseaseNCT03770299Disease-free survival (DFS)Randomized · Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Business objectives have changed | Biological: Nivolumab · Drug: Vinorelbine, Gemcitabine, Docetaxel, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel · Other: Observation | Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, Circulating Tumor DNA | 0 | 2023-03-14 | — | 2022-03-24 |
| A Phase 1, Bioavailability Study of Relatlimab in Combination With NivolumabNCT04112498maximum observed serum concentration (Cmax)Open-label · Treatment | Phase 1 | Completed | Drug: relatlimab, nivolumab, rHuPH20 | Cancer | 24 | 2023-02-27actual | — | 2023-04-06 |
| Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial FibrillationNCT03087487observationalTime to first major bleeding event | — | Completed | — | Non-Valvular Atrial Fibrillation | 466,991 | 2023-02-26actual | — | 2025-06-25 |
| A Study to Assess Safety of Nivolumab in Routine Oncology Practice in ChinaNCT04825873observationalIncidence rate of nivolumab-related immune-related adverse events (irAEs) | — | Completed | — | Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck | 3,102 | 2023-02-13actual | — | 2023-10-13 |
| Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast CancerNCT04109066results2024-03-12Pathological Complete Response (pCR) RateRandomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: nivolumab · Drug: paclitaxel (PTX), anthracycline, cyclophosphamide, Endocrine Therapy · Other: nivolumab placebo · Procedure: Surgery | Breast Cancer | 521 | 2023-01-16actual | — | 2025-01-08 |
| A Study of Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung CancerNCT05250817observationalSet of relative preference weights for all attribute levels included in the Discrete Choice Experiment (DCE) | — | Completed | — | Carcinoma, Non-Small-Cell Lung | 501 | 2023-01-04actual | — | 2023-06-09 |
| A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung CancerNCT05005273results2024-02-28Progression Free Survival by BICRRandomized · Triple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Nivolumab, Ipilimumab, BMS-986207 · Other: Placebo | Non-Small Cell Lung Cancer | 1 | 2022-12-27actual | — | 2024-02-28 |
| A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male ParticipantsNCT05567510Total radioactivity recovered in whole bloodOpen-label · Treatment | Phase 1 | Completed | Drug: BMS-986369 | Healthy Participants | 8 | 2022-12-27actual | — | 2023-02-17 |
| BMS-986012 in Relapsed/Refractory SCLCNCT02247349results2024-03-05Number of Participants With Adverse Events (AEs)Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: BMS-986012 (anti-fucosyl-GM1), Nivolumab | Small Cell Lung Cancer | 106 | 2022-12-21actual | — | 2024-03-05 |
| A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy ParticipantsNCT05337345Maximum observed concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Cendakimab | Healthy Volunteers | 104 | 2022-12-15actual | — | 2023-02-10 |
| An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's DiseaseNCT03599622results2024-07-03Percent of Participants Achieving Clinical Remission at Week 12Randomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Trial terminated because of lack of efficacy in the short term acute phase | Drug: BMS-986165 · Other: Placebo | Granulomatous Colitis, Crohn's Disease, Crohn's Enteritis, Granulomatous Enteritis | 239 | 2022-12-12actual | — | 2024-07-03 |
| Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid ArthritisNCT04186871results2024-01-16The Percent of Participants With mCLASI Response at Week 24 and Corticosteroid (CS) < 10 mg/Day at Week 20 and Week 24 - SLERandomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: branebrutinib, abatacept, branebrutinib placebo | Autoimmune Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sjögren's Syndrome | 119 | 2022-12-05actual | — | 2024-01-16 |
| A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of SulfasalazineNCT05445440Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC[0-T])Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Methotrexate, Leucovorin, BMS-986371, Sulfasalazine | Healthy Participants | 30 | 2022-11-17actual | — | 2023-02-08 |
| A Study to Evaluate the Safety, Tolerability, and Drug Levels of MYK-224 Administered in Single and Multiple Doses in Healthy Adult Japanese ParticipantsNCT05405543Maximum observed plasma concentration (Cmax)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: MYK-224 · Other: Placebo | Healthy Volunteers | 36 | 2022-11-16actual | — | 2023-01-13 |
| A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy ParticipantsNCT05093790results2023-12-05Percent Change From Baseline in Thrombus AreaNon-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Ticagrelor, BMS-986141, Aspirin | Coronary Artery Disease, Healthy Participants | 58 | 2022-11-14actual | — | 2023-12-05 |
| A Study to Assess the Drug Interaction Between MYK-224 and Itraconazole and Verapamil in Healthy ParticipantsNCT05304533Maximum observed plasma concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: MYK-224, Itraconazole, Verapamil | Healthy Participants | 45 | 2022-11-14actual | — | 2023-01-13 |
| A Taste Assessment of Iberdomide and Mezigdomide in Healthy ParticipantsNCT05539976observationalTaste Evaluation - Aromatic Identity | — | Completed | — | Healthy Participants | 10 | 2022-11-14actual | — | 2022-12-01 |
| A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy ParticipantsNCT05389722Maximum observed plasma concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: CC-92480, Rifampin, Itraconazole, Digoxin, Rosuvastatin | Healthy Volunteers | 24 | 2022-11-12actual | — | 2023-04-19 |
| Postmarketing Study of Empliciti in Korean Patients With Multiple MyelomaNCT03660072observationalIncidence of AE's and SAE's | — | Withdrawnsponsor's stated reason: Business objectives have changed | Other: Non-Interventional | Multiple Myeloma | 0 | 2022-10-28 | — | 2022-05-27 |
| A Study to Evaluate the Drug Levels of BMS-986166 in Healthy Male ParticipantsNCT05409157Total amount of total radioactivity (TRA) recovered in urine (UR)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BMS-986166, Bisacodyl | Healthy Participants | 7 | 2022-10-15actual | — | 2023-03-22 |
| A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy ParticipantsNCT05320094Area under the plasma concentration-time curve from time zero extrapolated to infinite time ((AUC(INF))Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Mavacamten, Activated Charcoal with Sorbitol | Healthy Participants | 45 | 2022-09-11actual | — | 2022-11-08 |
| A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)NCT03656718results2025-02-20Maximum Observed Serum Nivolumab Concentration (Cmax) - Parts A, B, D, and ERandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: nivolumab, nivolumab · Drug: rHuPH20 | Neoplasms by Site | 139 | 2022-09-07actual | — | 2025-11-12 |
| A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the BladderNCT03519256results2023-06-01Number of Participants With Adverse Events (AEs)Randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Insufficient Enrollment | Biological: Nivolumab, BCG · Drug: BMS-986205 | Urinary Bladder Neoplasms | 142 | 2022-08-22actual | — | 2023-06-01 |
| A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic DermatitisNCT05014438results2023-10-18Mean Percentage Change From Baseline in EASI Score at Week 16Randomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: BMS-986166, Branebrutinib · Other: Placebo | Dermatitis, Atopic | 17 | 2022-08-22actual | — | 2023-10-18 |
| A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy ParticipantsNCT05362045Maximum observed plasma concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Mavacamten | Healthy Participants | 158 | 2022-08-19actual | — | 2022-11-21 |
| A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy ParticipantsNCT05303220Maximum observed plasma concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Branebrutinib, Placebo | Healthy Volunteers | 56 | 2022-08-18actual | — | 2023-02-15 |
| A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has SpreadNCT04132817Incidence of Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Biological: Nivolumab, Ipilimumab · Drug: Nab-paclitaxel | Breast Cancer | 12 | 2022-08-15actual | — | 2022-12-02 |
| A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung FibrosisNCT04308681results2025-02-24Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC) in IPF ParticipantsRandomized · Triple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Other: BMS-986278 Placebo · Drug: BMS-986278 | Pulmonary Fibrosis | 403 | 2022-08-04actual | — | 2026-02-03 |
| A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class ExposureNCT05217082observationalHealth-Related Quality of Life (HRQoL) in specific domains: Fatigue, as measured by EORTC QLQ-C30 | — | Completed | — | Multiple Myeloma | 35 | 2022-08-03actual | — | 2023-06-09 |
| A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327NCT04069143Incidence of adverse events (AEs)Non-randomized · Open-label · Diagnostic | Phase 1 | Completed | Diagnostic test: 18F-BMS-986327 | Healthy Participants, Idiopathic Pulmonary Fibrosis (IPF) | 14 | 2022-07-12actual | — | 2023-03-07 |
| A Study to Evaluate the Drug Levels of [14C]CC-99677 in Healthy Male ParticipantsNCT05284890Maximum plasma concentration of the drug (Cmax) for CC-99677Open-label · Basic science | Phase 1 | Completed | Drug: CC-99677 | Healthy Volunteers | 8 | 2022-07-11actual | — | 2022-12-01 |
| A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-dose of Danicamtiv in Healthy ParticipantsNCT05162222Maximum observed plasma concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Danicamtiv, Itraconazole, Diltiazem | Healthy Participants | 30 | 2022-07-08actual | — | 2022-08-10 |
| A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed ConditionsNCT05236738Maximum observed plasma concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Atazanavir, Cobicistat, Atazanavir/Cobicistat Mini-tablet | Healthy Participants | 42 | 2022-07-05actual | — | 2022-10-31 |
| A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant CancerNCT04730349results2023-03-24Number of Participants With Dose-Limiting Toxicities (DLTs) - Part ANon-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Business objectives have changed | Biological: Nivolumab, NKTR-214 | Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma, Medulloblastoma, Miscellaneous Brain Tumors, Miscellaneous Solid Tumors, Neuroblastoma, Relapsed, Refractory Malignant Neoplasms, Rhabdomyosarcoma | 15 | 2022-06-22actual | — | 2023-03-24 |
| Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United StatesNCT03045120observationalchanges in cardiovascular risk from baseline using the Framingham Coronary Heart Disease Score | — | Completed | — | Chronic Phase Chronic Myeloid Leukemia | 118 | 2022-06-20actual | — | 2022-12-21 |
| A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy ParticipantsNCT04882150Incidence of Adverse Events (AEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: BMS-986196 · Other: Placebo | Healthy Participants | 102 | 2022-06-10actual | — | 2023-01-12 |
| Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With NivolumabNCT03200977observationalTreatment-Related Mortality (TRM) | — | Completed | Other: Non-Interventional | Lymphoma | 95 | 2022-06-03actual | — | 2025-03-26 |
| A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver ImpairmentNCT04634149Maximum observed plasma concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BMS-986036 | Moderate Liver Impairment, Severe Liver Impairment | 16 | 2022-06-02actual | — | 2022-06-16 |
| A Study of Adjuvant Melanoma Stakeholder Treatment PreferencesNCT05115006observationalPreference weights or utilities (a measure of relative preference; on a continuous variable scale) for each treatment attribute level based on responses to the Discrete Choice Experiment (DCE) choice tasks | — | Completed | — | Melanoma | 294 | 2022-06-02actual | — | 2022-06-30 |
| Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating DasatinibNCT02297139results2023-05-06Number of Participants Who Received Dasatinib TreatmentOpen-label · Supportive careStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Dasatinib | Multiple Indications Cancer | 17 | 2022-05-15actual | — | 2023-05-06 |
| An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced CancersNCT02869789results2023-06-15Number of Participants With High Grade (Grade 3-4 and Grade 5) Drug-Related Select Adverse Events (AEs)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Nivolumab in combination with Ipilimumab | Lung Cancer | 1,041 | 2022-05-13actual | — | 2023-06-15 |
| A Study to Test Combination Treatments in Participants With Advanced Gastric CancerNCT02935634results2023-06-09Objective Response Rate (ORR) by InvestigatorRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Nivolumab, Ipilimumab, Relatlimab, BMS-986205 · Drug: Rucaparib | Advanced Gastric Cancer | 190 | 2022-05-11actual | — | 2023-06-09 |
| A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)NCT03668119results2023-05-18Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) - Arm ARandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Nivolumab, Ipilimumab | Pan Tumor | 212 | 2022-05-03actual | — | 2024-08-28 |
| A Study to Assess the Effect of Itraconazole, Phenytoin and Gemfibrozil on the Drug Levels of BMS-986166 in Healthy ParticipantsNCT04956627Maximum observed plasma concentration (Cmax) of BMS-986166Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: BMS-986166, Itraconazole, Extended Phenytoin Sodium, Gemfibrozil | Healthy Participants | 15 | 2022-04-27actual | — | 2022-05-13 |
| A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)NCT02985957results2023-04-24Objective Response Rate (ORR) Cohorts B and C Per BICRRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Nivolumab, Ipilimumab · Drug: Cabazitaxel, Prednisone | Prostate Cancer | 351 | 2022-04-05actual | — | 2025-12-22 |
| Safety and Effectiveness of Abatacept in Psoriatic Arthritis ParticipantsNCT03419143observationalDisease Activity index for PSoriatic Arthritis (DAPSA) | — | Completed | — | Psoriatic Arthritis (PsA) | 190 | 2022-03-31actual | — | 2022-05-31 |
| A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and ClopidogrelNCT03766581results2023-06-12Percent of Participants With Model Based Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90Randomized · Quadruple-masked · PreventionStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: BMS-986177, Clopidogrel, Aspirin · Other: Placebo | Acute Ischemic Stroke, Transient Ischemic Attack (TIA) | 2,366 | 2022-03-31actual | — | 2023-06-12 |
| A Study of Abatacept in Participants That Only Recently Started to Develop Rheumatoid ArthritisNCT03457792observationalNumber of patients continuing with abatacept treatment | — | Completed | — | Rheumatoid Arthritis | 158 | 2022-03-30actual | — | 2022-06-14 |
| An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple MyelomaNCT02726581results2023-03-27Progression Free Survival (PFS)Randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Nivolumab, Elotuzumab · Drug: Pomalidomide, Dexamethasone | Multiple Myeloma | 170 | 2022-03-09actual | — | 2023-03-27 |
| A Study Evaluating Quality of Life for Participants With Atrial Fibrillation (AF) Following a Bleed (EQUAL-AF)NCT05044533observationalDistribution of characteristics of AF participants: Quality of life (QoL) data | — | Completed | — | Atrial Fibrillation | 50 | 2022-03-09actual | — | 2023-06-18 |
| An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction AdenocarcinomaNCT03704077Overall response rate (ORR)Randomized · Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Replaced it with another clinical trial | Biological: Relatlimab + Nivolumab, Nivolumab · Drug: Paclitaxel, Ramucirumab | Gastric Cancer, Cancer of the Stomach, Stomach Cancer, Gastroesophageal Junction | 0 | 2022-02-27 | — | 2020-05-19 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy ParticipantsNCT04763226Incidence of Adverse Events (AEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: BMS-986308, Furosemide · Other: Placebo (for BMS-986308) | Healthy Participants | 46 | 2022-02-27actual | — | 2022-04-27 |
| An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)NCT03001882results2023-06-06Objective Response Rate (ORR) Per Investigator by Blood TMB (bTMB) Within PD-L1 Subgroup (TMB Cut-point = 16 Mutations/MB)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Nivolumab, Ipilimumab | Non-Small Cell Lung Cancer | 230 | 2022-02-17actual | — | 2024-05-20 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell MalignanciesNCT02061761results2023-03-24Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to DiscontinuationNon-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: BMS-986016, BMS-936558 | Hematologic Neoplasms | 106 | 2022-02-16actual | — | 2023-03-24 |
| An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be RemovedNCT03444753Incidence of dose-limiting toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: business objectives have changed | Drug: BMS-986299 · Biological: Nivolumab, Ipilimumab | Advanced Cancer | 82 | 2022-02-14actual | — | 2022-05-23 |
| A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction TherapyNCT04349072results2023-03-07Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16Randomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Mavacamten, Placebo | HOCM, Hypertrophic Obstructive Cardiomyopathy | 112 | 2022-02-07actual | — | 2025-05-23 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986166 in Healthy Japanese ParticipantsNCT04965402Pharmacokinetic (PK) parameters of BMS-986166: Maximum observed blood concentration (Cmax)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: BMS-986166 · Other: Placebo | Healthy Volunteers | 23 | 2022-02-07actual | — | 2022-03-09 |
| Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice ExperimentNCT05065762observationalPsoriasis (PsO) patient preferences of moderate-to-severe systemic treatment atrribute | — | Completed | — | Psoriasis | 232 | 2022-02-07actual | — | 2022-06-06 |
| A Study to Characterize the Drug Levels of an Oral Contraceptive With and Without BMS-986166 in Healthy Female Participants of Childbearing PotentialNCT04934696Geometric means ratio of Cmax of NETOpen-label · Basic science | Phase 1 | Completed | Drug: BMS-986166, Oral contraceptive | Healthy Participants | 25 | 2022-01-25actual | — | 2022-03-18 |
| A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) TherapyNCT02864251results2023-02-06Progression Free Survival (PFS) by Blinded Independent Centralized Review (BICR)Randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Nivolumab, Ipilimumab · Drug: Pemetrexed, Cisplatin, Carboplatin | Non-Small-Cell Lung Carcinoma | 367 | 2022-01-20actual | — | 2023-09-28 |
| A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy ParticipantsNCT04949269Maximum Observed Plasma Concentration (Cmax) of deucravacitinibRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Deucravacitinib, Famotidine | Healthy Participants | 61 | 2022-01-03actual | — | 2022-03-11 |
| A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 AbsorptionNCT04926051Incidence of non-serious Adverse Events (AEs)Randomized · Quadruple-masked · Basic science | Phase 1 | Completed | Drug: BMS-986172 · Other: Placebo | Healthy Participants | 40 | 2021-12-28actual | — | 2022-06-06 |
| A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult ParticipantsNCT05051553Fedratinib Pharmacokinetics: Estimation of maximum observed plasma concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Fedratinib | Healthy Volunteers | 58 | 2021-12-23actual | — | 2022-06-27 |
| A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid TumorsNCT03251924results2023-02-28The Number of Participants Experiencing Adverse Events (AEs)Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Study CA021-002 was terminated because the Sponsor discontinued further development of BMS-986226 due to a change in business objectives. The decision for the study closure was not related to any safety concerns associated with BMS-986226. | Drug: BMS-986226 · Biological: Nivolumab, Ipilimumab, Tetanus Vaccine | Cancer, Tumors, Neoplasm, Malignancy | 80 | 2021-12-20actual | — | 2023-02-28 |
| A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in JapanNCT05027061observationalSpecialization of the treating physician | — | Completed | — | Non-Valvular Atrial Fibrillation (NVAF) | 11,776 | 2021-12-04actual | — | 2022-03-17 |
| A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United KingdomNCT04936399observationalDistribution of demographic characteristics of NSCLC participants treated with nivolumab at initiation of nivolumab treatment: Age | — | Completed | Biological: Nivolumab | Esophageal Squamous Cell Carcinoma | 87 | 2021-12-03actual | — | 2022-05-25 |
| A Study to Test Combination Treatments in People With Advanced Renal Cell CarcinomaNCT02996110results2022-12-19Objective Response Rate (ORR) Per InvestigatorRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Nivolumab, Ipilimumab, Relatlimab · Drug: BMS-986205, BMS-813160 | Advanced Cancer | 182 | 2021-11-23actual | — | 2022-12-19 |
| A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic MelanomaNCT03635983results2022-12-19Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR)Randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: NKTR-214, Nivolumab | Melanoma | 783 | 2021-11-19actual | — | 2025-04-01 |
| A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell CarcinomaNCT04088500results2023-01-10Disease Control Rate (DCR)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Slow accrual | Biological: Nivolumab, Ipilimumab | Renal Cell Carcinoma | 5 | 2021-11-15actual | — | 2023-01-10 |
| An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have SpreadNCT02658890results2023-08-28Number of Participants With AEs, SAEs, AEs Leading to Discontinuation and DeathsRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: BMS-986205, Nivolumab, Ipilimumab | Advanced Cancer, Melanoma, Non-Small Cell Lung Cancer | 627 | 2021-10-26actual | — | 2023-08-28 |
| A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring AnticoagulationNCT02981472results2022-05-18Composite of Adjudicated Major or Clinically Relevant Non-Major (CRNM) Bleeding EventsRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Apixaban, Vitamin K Antagonist (VKA), Low Molecular Weight Heparin (LMWH) | Thrombosis | 192 | 2021-10-18actual | — | 2022-10-03 |
| A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)NCT05068609observationalDistribution of demographic characteristics of R/M SCCHN participants treated with nivolumab: Month and year of birth | — | Completed | Biological: Nivolumab | Squamous Cell Carcinoma of the Head and Neck | 509 | 2021-10-18actual | — | 2022-05-05 |
| An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With NivolumabNCT02754141results2023-04-05Number of Participants With Drug Related AEs, SAEs, AEs Leading to Discontinuation and Deaths.Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: BMS-986179, Nivolumab, rHuPH20 | Malignant Solid Tumor | 235 | 2021-10-12actual | — | 2023-04-05 |
| A Study of Treatment Patterns and Clinical Outcomes of Psoriasis in JapanNCT04826536observationalDistribution of participant background at first visit: Age | — | Completed | — | Psoriasis | 114 | 2021-10-08actual | — | 2022-06-03 |
| A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy RegimenNCT02066636results2022-10-27The Number of Participants With Treatment Related Select Adverse Events (Grade 3-4 and Grade 5)Randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Nivolumab | Non Small Cell Lung Cancer (NSCLC) | 1,428 | 2021-10-06actual | — | 2022-10-27 |
| A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid TumorsNCT02593786results2022-10-24The Number of Participants Experiencing Drug-Related Grade 3-4 Adverse Events (AEs)Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Nivolumab | Solid Tumors | 58 | 2021-09-27actual | — | 2022-10-24 |
| A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy ParticipantsNCT04941755Maximum observed plasma concentration (Cmax) of BMS-986256Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: BMS-986256, Famotidine | Healthy Participants | 22 | 2021-09-24actual | — | 2022-01-21 |
| A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean ParticipantsNCT04649710Maximum observed plasma concentration (Cmax) of C-terminal intact BMS-986036 in Chinese and Korean participantsRandomized · Triple-masked · Treatment | Phase 1 | Withdrawnsponsor's stated reason: Business objectives have changed | Biological: BMS-986036 · Other: Placebo | Healthy Participants | 0 | 2021-09-21 | — | 2022-04-28 |
| Taste Assessment of OzanimodNCT05001152Taste evaluation - Aromatic identityOpen-label · Treatment | Phase 1 | Completed | Drug: Ozanimod | Healthy Volunteers | 7 | 2021-09-17actual | — | 2023-06-18 |
| Taste Properties of Atazanavir and CobicistatNCT02307656Taste properties of ATV & COBI alone & in combination as well as oral test formulations containing both ATV & COBI Aromatic identity will be measured using the Flavor Profile of the Flavor Leadership CriteriaOpen-label · Other | Phase 1 | Completed | Drug: Atazanavir, Cobicistat, Active Pharmaceutical Ingredient | HIV in Adults | 6 | 2021-09-09actual | — | 2022-01-05 |
| A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)NCT02998528results2022-09-28Event-Free Survival (EFS)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Nivolumab, Ipilimumab · Drug: Cisplatin, Vinorelbine, Gemcitabine, Docetaxel, Pemetrexed, Carboplatin, Paclitaxel | Non Small Cell Lung Cancer | 505 | 2021-09-08actual | — | 2026-01-06 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of Single and Multiple Doses of BMS-986209 in Healthy ParticipantsNCT04154800Incidence of Adverse Events (AEs) including bleedingRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: BMS-986209, Itraconazole, Diltiazem · Other: BMS-986209 Placebo | Health Participants | 114 | 2021-08-31actual | — | 2022-01-04 |
| A Study of Milvexian Using an IV Microtracer With Additional Formulation and Food Effect Comparison in Healthy ParticipantsNCT04965389results2023-08-21Absolute Bioavailability (F)Randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: BMS-986177 Oral Solution, [14C]BMS-986177 Solution for Infusion, BMS-986177 Spray-dried Dispersion Capsules | Healthy Volunteers | 17 | 2021-08-22actual | — | 2023-08-21 |
| A Study of Participants in Australia Who Have Non-small Cell Lung Cancer Being Treated With NivolumabNCT03804554observationalTime to treatment failure (TTF) | — | Completed | Other: Non-Interventional | Non-Small Cell Lung Cancer | 503 | 2021-08-12actual | — | 2022-05-27 |
| Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory CompromiseNCT04472494results2022-10-07Percentage of Participants on Invasive Mechanical Ventilation or Died Prior to or on Day 28Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Slow accrual | Biological: Abatacept · Other: Placebo | COVID-19, SARS-CoV-2 | 61 | 2021-08-12actual | — | 2022-10-07 |
| A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver DiseaseNCT04766476Incidence of adverse events (AEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Business objectives have changed | Drug: BMS-963272 · Other: Placebo matching BMS-963272 | Nonalcoholic Fatty Liver Disease | 9 | 2021-08-12actual | — | 2022-06-09 |
| A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast CancerNCT04075604results2022-08-10The Number of Participants With Dose Limiting Toxicities (DLT) in the Safety Run-in PhaseRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Nivolumab · Drug: Anastrozole, Palbociclib | Breast Cancer, Cancer | 23 | 2021-07-27actual | — | 2022-08-10 |
| Study of the Safety of Orencia in Japanese Children and Adolescents With Active Juvenile Arthritis of Unknown OriginNCT03466814observationalNumber of adverse events | — | Completed | Other: Non-Interventional | Undifferentiated Arthritis | 82 | 2021-07-21actual | — | 2022-06-16 |
| Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart FailureNCT04318093results2022-08-04Percentage of Participants Experiencing Clinically Relevant HypotensionRandomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: BMS-986259 · Other: Placebo | Acute Decompensated Heart Failure | 25 | 2021-07-19actual | — | 2022-08-04 |
| A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney FunctionNCT04237831Maximum plasma Concentration (Cmax) of BMS-986259 in Blood serumNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BMS-986259 | Renal Failure | 30 | 2021-07-16actual | — | 2021-09-24 |
| A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy ParticipantsNCT04175925Incidence of DeathRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: BMS-986322, famotidine · Other: BMS-986322 Placebo | Healthy Participants | 171 | 2021-07-13actual | — | 2022-05-31 |
| A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With AsparaginaseNCT02369653results2022-03-08The Number of Participants With Non-Fatal DVT, PE, and CVST, and VTE-Related-DeathRandomized · Open-label · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Apixaban · Other: No systemic anticoagulant prophylaxis | Lymphoma, Acute Lymphoblastic Leukemia | 512 | 2021-07-07actual | — | 2022-03-08 |
| A Study of Experimental Medication BMS-986235 in Healthy SubjectsNCT03335553Number of serious adverse events (SAE)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: BMS-986235 · Other: Placebo | Mediators of Inflammation | 122 | 2021-07-02actual | — | 2022-03-31 |
| An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus ErythematosusNCT03252587results2022-09-10Number of Participants Who Meet Response Criteria for Systemic Lupus Erythematosus (SLE) Responder Index [SRI(4)] at Week 32Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: BMS-986165 · Other: Placebo | Systemic Lupus Erythematosus | 363 | 2021-06-29actual | — | 2022-12-20 |
| Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative ColitisNCT03934216results2022-07-06Clinical Remission Response Rate at Week 12Randomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: BMS-986165 · Other: Placebo | Ulcerative Colitis | 131 | 2021-06-13actual | — | 2024-03-06 |
| Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled SyringeNCT04493567Maximum observed serum concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BMS-986036 | Healthy Participants | 102 | 2021-06-11actual | — | 2022-03-18 |
| A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in AsiaNCT03195491results2024-07-18Number of Non-HBV Participants Experiencing High Grade Treatment-Related Select Adverse EventsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Nivolumab | Lung Cancer, Non-Small Cell Lung Cancer | 400 | 2021-06-08actual | — | 2024-07-18 |
| A Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Drug Levels and Safety of BMS-986235NCT04464577Area under the plasma concentration-time curve from time 0 to time of last quantifiable concentration (AUC(0-T)) of BMS-986235 with fluconazoleNon-randomized · Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: Business objectives have changed. | Drug: Fluconazole, Bupropion, Itraconazole, BMS-986235 | Healthy Participants | 0 | 2021-06-07 | — | 2022-03-25 |
| A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver ImpairmentNCT04225936Maximum observed serum concentration (Cmax) of components of BMS-986263 for injectionNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BMS-986263 | Hepatic Impairment | 40 | 2021-06-01actual | — | 2021-11-05 |
| Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy ParticipantsNCT04444050Number of participants with adverse events (AEs)Randomized · Triple-masked · Basic science | Phase 1 | Completed | Drug: BMS-986331 · Other: Placebo, Matching BMS-986331 | Healthy Participants | 48 | 2021-05-19actual | — | 2022-10-20 |
| Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckNCT02741570results2022-05-03Overall Survival (OS) in Participants With Programmed Death-Ligand 1 (PD-L1) With a Combined Positive Score (CPS) ≥20Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Nivolumab, Ipilimumab · Drug: Cetuximab/Erbitux, Cisplatin/Platinol, Carboplatin/Paraplatin, Fluorouracil/Adrucil | Head and Neck Cancer | 947 | 2021-05-10actual | — | 2023-09-21 |
| An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung CancerNCT03417037Objective response rate (ORR) measured by number of participants with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) divided by the number of randomized participants for each treatment groupRandomized · Open-label · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Business objectives have changed. | Drug: BMS-986205, Chemotherapy · Biological: Nivolumab | Lung Cancer, Non-Small Cell Lung Cancer | 0 | 2021-04-25 | — | 2018-04-30 |
| Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male ParticipantsNCT04567667Maximum observed plasma concentration (Cmax) of BMS-986278Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: [14C] BMS-986278, Kinevac® | Healthy Volunteers | 9 | 2021-04-11actual | — | 2022-06-02 |
| An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker AssessmentNCT03335540Number of participants with qualified tumor biopsy specimen at baselineRandomized · Open-label · Treatment | Phase 1 | Completed | Biological: Nivolumab, Relatlimab, Cabiralizumab, Ipilimumab · Drug: IDO1 Inhibitor · Radiation: Radiation Therapy | Advanced Cancer | 20 | 2021-03-31actual | — | 2022-09-26 |
| Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male ParticipantsNCT04269356Maximum observed plasma concentration (Cmax) of [14C] BMS-986256Open-label · Treatment | Phase 1 | Completed | Drug: BMS-986256, Milk of magnesia | Healthy Participants | 8 | 2021-03-30actual | — | 2022-01-10 |
| A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the USNCT03732560observationalOverall Survival (OS) from Advanced Diagnosis | — | Completed | Other: Non-Interventional | Melanoma | 600 | 2021-03-25actual | — | 2022-12-08 |
| An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe PsoriasisNCT03924427results2022-11-02Static Physician's Global Assessment (sPGA) 0/1 Response as a Number of Participants With a sPGA Score of 0 or 1 at Week 16Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: BMS-986165 | Psoriasis | 74 | 2021-03-24actual | — | 2022-11-02 |
| Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy ParticipantsNCT04470778Maximum observed plasma concentration (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BMS-986256, Famotidine | Healthy Participants | 35 | 2021-03-21actual | — | 2025-02-06 |
| An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated TumorsNCT02488759results2022-04-12Neoadjuvant: Number of Participants With Drug-Related Select Adverse Events (AEs)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Nivolumab, Ipilimumab, Relatlimab, Daratumumab | Various Advanced Cancer | 578 | 2021-03-19actual | — | 2023-11-13 |
| A Study of Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (1L R/M SCCHN) Participants in EuropeNCT05123950observationalDistribution of demographic characteristics of 1L R/M SCCHN participants treated with nivolumab: Age | — | Completed | — | Squamous Cell Carcinoma of the Head and Neck | 304 | 2021-03-19actual | — | 2021-11-17 |
| Study of BMS-986158 in Subjects With Select Advanced CancersNCT02419417results2022-06-16Number of Participants Experiencing Adverse EventsNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: BMS-986158 · Biological: Nivolumab | Advanced Tumors | 83 | 2021-03-17actual | — | 2022-06-16 |
| An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South KoreaNCT04167462results2022-11-02The Percentage of Participants With sPGA Response of 0 or 1Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: BMS-986165 · Other: Placebo | Psoriasis | 220 | 2021-03-08actual | — | 2023-03-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19